menu
    • menu
    [{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Shanghai Institute of Materia Medica","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"SIM0417","moa":"3CLpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Shanghai Institute of Materia Medica","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Shanghai Institute of Materia Medica"},{"orgOrder":0,"company":"The Aurum Institute NPC","sponsor":"Ludwig Maximilian University of Munich | Stichting Katholieke Universiteit | Wits Health Consortium | Instituto Nacional de Sa\u00fade, Mozambique | National Institute for Medical Research, Tanzania | University of Stellenbosch | Sequella, Inc. | TB Alliance","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sutezolid","moa":"70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"The Aurum Institute NPC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Aurum Institute NPC \/ Ludwig Maximilian University of Munich | Stichting Katholieke Universiteit | Wits Health Consortium | Instituto Nacional de Sa\u00fade, Mozambique | National Institute for Medical Research, Tanzania | University of Stellenbosch | Sequella, Inc. | TB Alliance","highestDevelopmentStatusID":"9","companyTruncated":"The Aurum Institute NPC \/ Ludwig Maximilian University of Munich | Stichting Katholieke Universiteit | Wits Health Consortium | Instituto Nacional de Sa\u00fade, Mozambique | National Institute for Medical Research, Tanzania | University of Stellenbosch | Sequella, Inc. | TB Alliance"},{"orgOrder":0,"company":"APR Applied Pharma Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"APR Applied Pharma Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"APR Applied Pharma Research \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"APR Applied Pharma Research \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Advita","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Advita","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Advita"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Partnership","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"Relief Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Relief Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Relief Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Relief Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"UCI Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"UCI Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"UCI Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"UCI Health \/ Undisclosed"},{"orgOrder":0,"company":"Mannkind","sponsor":"NRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Partnership","leadProduct":"Aviptadil Acetate","moa":"Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Mannkind","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mannkind \/ NRx Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Mannkind \/ NRx Pharmaceuticals"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Aviptadil Acetate","moa":"||Adrenergic receptor alpha","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Cardiothoracic Surgical Trials Network","sponsor":"Mesoblast","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Partnership","leadProduct":"Remestemcel-L","moa":"Alloreactive T lymphocyte","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiothoracic Surgical Trials Network","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardiothoracic Surgical Trials Network \/ Mesoblast","highestDevelopmentStatusID":"9","companyTruncated":"Cardiothoracic Surgical Trials Network \/ Mesoblast"},{"orgOrder":0,"company":"Institute for Human Genetics and Biochemistry","sponsor":"AIDS Community Research Initiative of America | Grifols International","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Alpha-1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Institute for Human Genetics and Biochemistry","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute for Human Genetics and Biochemistry \/ AIDS Community Research Initiative of America | Grifols International","highestDevelopmentStatusID":"9","companyTruncated":"Institute for Human Genetics and Biochemistry \/ AIDS Community Research Initiative of America | Grifols International"},{"orgOrder":0,"company":"Institute for Human Genetics and Biochemistry","sponsor":"CSL Behring","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"Alpha-1 Proteinase Inhibitor","moa":"Alpha-1 antitrypsin","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Institute for Human Genetics and Biochemistry","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute for Human Genetics and Biochemistry \/ CSL Behring","highestDevelopmentStatusID":"9","companyTruncated":"Institute for Human Genetics and Biochemistry \/ CSL Behring"},{"orgOrder":0,"company":"Nabriva Therapeutics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"ZTI-01","moa":"antibiotics (Streptomyces strains); phosphoro-derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Nabriva Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nabriva Therapeutics \/ Medpace, Inc","highestDevelopmentStatusID":"9","companyTruncated":"Nabriva Therapeutics \/ Medpace, Inc"},{"orgOrder":0,"company":"Australian National University","sponsor":"Helwan University | Clinica San Camilo, Argentina | Frederick Health | Coney Island Hospital, Brooklyn, NY | Galeno Desenvolvimento de Pesquisas Cl\u00ednicas | Dr Cipto Mangunkusumo General Hospital | Dr. Moewardi General Hospital, Surakarta, Indonesia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Heparin Sodium","moa":"Antithrombin-III","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Australian National University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nebulizer","sponsorNew":"Australian National University \/ Helwan University | Clinica San Camilo, Argentina | Frederick Health | Coney Island Hospital, Brooklyn, NY | Galeno Desenvolvimento de Pesquisas Cl\u00ednicas | Dr Cipto Mangunkusumo General Hospital | Dr. Moewardi General Hospital, Surakarta, Indonesia","highestDevelopmentStatusID":"9","companyTruncated":"Australian National University \/ Helwan University | Clinica San Camilo, Argentina | Frederick Health | Coney Island Hospital, Brooklyn, NY | Galeno Desenvolvimento de Pesquisas Cl\u00ednicas | Dr Cipto Mangunkusumo General Hospital | Dr. Moewardi General Hospital, Surakarta, Indonesia"},{"orgOrder":0,"company":"Georgia State University Institute","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Georgia State University Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Georgia State University Institute \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Georgia State University Institute \/ Merck & Co"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Molnupiravir","moa":"antivirals","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institutes of Health \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ Undisclosed"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Protein","year":"2025","type":"Funding","leadProduct":"CER-001","moa":"Apolipoprotein A-I (APOA1)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abionyx Pharma","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Abionyx Pharma \/ Bpifrance","highestDevelopmentStatusID":"9","companyTruncated":"Abionyx Pharma \/ Bpifrance"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"CER-001","moa":"Apolipoprotein A-I (APOA1)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Abionyx Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abionyx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Abionyx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"CER-001","moa":"Apolipoprotein A-I (APOA1)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abionyx Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Abionyx Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abionyx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"M\u00e9decins Sans Fronti\u00e8res Netherlands","sponsor":"London School of Hygiene & Tropical Medicine | TB Alliance | University College, London | Drugs for Neglected Diseases | Swiss Tropical and Public Health Institute | eResearch Technology | Ministry of Health, Uzbekistan | World Health Organization | Minis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"M\u00e9decins Sans Fronti\u00e8res Netherlands","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M\u00e9decins Sans Fronti\u00e8res Netherlands \/ London School of Hygiene & Tropical Medicine | TB Alliance | University College, London | Drugs for Neglected Diseases | Swiss Tropical and Public Health Institute | eResearch Technology | Ministry of Health, Uzbekistan | World Health Organization | Minis","highestDevelopmentStatusID":"9","companyTruncated":"M\u00e9decins Sans Fronti\u00e8res Netherlands \/ London School of Hygiene & Tropical Medicine | TB Alliance | University College, London | Drugs for Neglected Diseases | Swiss Tropical and Public Health Institute | eResearch Technology | Ministry of Health, Uzbekistan | World Health Organization | Minis"},{"orgOrder":0,"company":"M\u00e9decins Sans Fronti\u00e8res Netherlands","sponsor":"London School of Hygiene & Tropical Medicine | TB Alliance | University College, London | Drugs for Neglected Diseases | Swiss Tropical and Public Health Institute | eResearch Technology | Ministry of Health, Uzbekistan | World Health Organization | Minis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"M\u00e9decins Sans Fronti\u00e8res Netherlands","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M\u00e9decins Sans Fronti\u00e8res Netherlands \/ London School of Hygiene & Tropical Medicine | TB Alliance | University College, London | Drugs for Neglected Diseases | Swiss Tropical and Public Health Institute | eResearch Technology | Ministry of Health, Uzbekistan | World Health Organization | Minis","highestDevelopmentStatusID":"9","companyTruncated":"M\u00e9decins Sans Fronti\u00e8res Netherlands \/ London School of Hygiene & Tropical Medicine | TB Alliance | University College, London | Drugs for Neglected Diseases | Swiss Tropical and Public Health Institute | eResearch Technology | Ministry of Health, Uzbekistan | World Health Organization | Minis"},{"orgOrder":0,"company":"M\u00e9decins Sans Fronti\u00e8res Netherlands","sponsor":"London School of Hygiene & Tropical Medicine | Ministry of Health, Uzbekistan | Ministry of Public Health, Belarus | THINK TB & HIV Network | University of Liverpool | Wits Health Consortium","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"M\u00e9decins Sans Fronti\u00e8res Netherlands","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"M\u00e9decins Sans Fronti\u00e8res Netherlands \/ London School of Hygiene & Tropical Medicine | Ministry of Health, Uzbekistan | Ministry of Public Health, Belarus | THINK TB & HIV Network | University of Liverpool | Wits Health Consortium","highestDevelopmentStatusID":"9","companyTruncated":"M\u00e9decins Sans Fronti\u00e8res Netherlands \/ London School of Hygiene & Tropical Medicine | Ministry of Health, Uzbekistan | Ministry of Public Health, Belarus | THINK TB & HIV Network | University of Liverpool | Wits Health Consortium"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bedaquiline","moa":"ATP synthase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Fiocruz","sponsor":"Pan American Health Organization | Ministry of Health, Brazil | University of Sao Paulo","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Artesunate","moa":"antimalarials (artemisin dervatives)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Fiocruz","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fiocruz \/ Pan American Health Organization | Ministry of Health, Brazil | University of Sao Paulo","highestDevelopmentStatusID":"9","companyTruncated":"Fiocruz \/ Pan American Health Organization | Ministry of Health, Brazil | University of Sao Paulo"},{"orgOrder":0,"company":"Kevin Winthrop","sponsor":"Patient-Centered Outcomes Research Institute | National Jewish Health | University of Texas Health Science Center at Tyler | University Health Network, Toronto | New York University | Medical University of South Carolina | Mayo Clinic | LSU Health Science","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Azithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kevin Winthrop","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kevin Winthrop \/ Patient-Centered Outcomes Research Institute | National Jewish Health | University of Texas Health Science Center at Tyler | University Health Network, Toronto | New York University | Medical University of South Carolina | Mayo Clinic | LSU Health Science","highestDevelopmentStatusID":"9","companyTruncated":"Kevin Winthrop \/ Patient-Centered Outcomes Research Institute | National Jewish Health | University of Texas Health Science Center at Tyler | University Health Network, Toronto | New York University | Medical University of South Carolina | Mayo Clinic | LSU Health Science"},{"orgOrder":0,"company":"University Medical Center Groningen","sponsor":"University of Groningen | Facult\u00e9 de M\u00e9decine P&M Curie, Paris-6 - Site Piti\u00e9-Salp\u00eatri\u00e8re, France | Drugs for Neglected Diseases | World Alliance for Wound and Lymphoedema Care, Switzerland | Inserm U892\/CNRS 699 bact\u00e9riologie, Universit\u00e9 CHU;Angers- IRIS","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Antibiotic","year":"2012","type":"Inapplicable","leadProduct":"Clarithromycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University Medical Center Groningen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Medical Center Groningen \/ University of Groningen | Facult\u00e9 de M\u00e9decine P&M Curie, Paris-6 - Site Piti\u00e9-Salp\u00eatri\u00e8re, France | Drugs for Neglected Diseases | World Alliance for Wound and Lymphoedema Care, Switzerland | Inserm U892\/CNRS 699 bact\u00e9riologie, Universit\u00e9 CHU;Angers- IRIS","highestDevelopmentStatusID":"9","companyTruncated":"University Medical Center Groningen \/ University of Groningen | Facult\u00e9 de M\u00e9decine P&M Curie, Paris-6 - Site Piti\u00e9-Salp\u00eatri\u00e8re, France | Drugs for Neglected Diseases | World Alliance for Wound and Lymphoedema Care, Switzerland | Inserm U892\/CNRS 699 bact\u00e9riologie, Universit\u00e9 CHU;Angers- IRIS"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Neomycin","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Medical University Cancer Institute and Hospital","sponsor":"Zhejiang Hisun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tigecycline","moa":"Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Tianjin Medical University Cancer Institute and Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tianjin Medical University Cancer Institute and Hospital \/ Zhejiang Hisun Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Tianjin Medical University Cancer Institute and Hospital \/ Zhejiang Hisun Pharmaceutical"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Benapenem","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sihuan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sihuan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sihuan Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Benapenem","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sihuan Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sihuan Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sihuan Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lumen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Funding","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Lumen Bioscience \/ US Department of Defense","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ US Department of Defense"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Lumen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Congressionally Directed Medical Research Programs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lumen Bioscience \/ Congressionally Directed Medical Research Programs","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ Congressionally Directed Medical Research Programs"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"LMN-201","moa":"Bacterial cell wall synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lumen Bioscience \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Lumen Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Peschke","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Moxifloxacin","moa":"Bacterial DNA gyrase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peschke","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Peschke \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peschke \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2019","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Imipenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Medical University Cancer Institute and Hospital","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Piperacillin Sodium","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Tianjin Medical University Cancer Institute and Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Tianjin Medical University Cancer Institute and Hospital \/ Pfizer Inc","highestDevelopmentStatusID":"9","companyTruncated":"Tianjin Medical University Cancer Institute and Hospital \/ Pfizer Inc"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Potravitug","moa":"Betapolyomavirus","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Ysios Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Series C Financing","leadProduct":"Potravitug","moa":"Betapolyomavirus","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Memo Therapeutics \/ Ysios Capital","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Ysios Capital"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Potravitug","moa":"Betapolyomavirus","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Potravitug","moa":"Betapolyomavirus","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Potravitug","moa":"Betapolyomavirus","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Resverlogix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Apabetalone","moa":"Bromodomain and extra-terminal motif (BET)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Resverlogix","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Resverlogix \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Resverlogix \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zavegepant HCl","moa":"Calcitonin-gene-related peptide receptor, CALCRL\/RAMP1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cardiol Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cardiol Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Cardiol Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Cardiol Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Cellular Sciences","sponsor":"Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Pyruvate","moa":"Carbonic anhydrase IV (CA-IV)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cellular Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cellular Sciences \/ Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague","highestDevelopmentStatusID":"9","companyTruncated":"Cellular Sciences \/ Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague"},{"orgOrder":0,"company":"Cellular Sciences","sponsor":"Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sodium Pyruvate","moa":"Carbonic anhydrase IV (CA-IV)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cellular Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cellular Sciences \/ Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague","highestDevelopmentStatusID":"9","companyTruncated":"Cellular Sciences \/ Missouri State University | Dynamic DNA Laboratories | Trinity Health System | General University Hospital, Prague"},{"orgOrder":0,"company":"Laboratorio Elea Phoenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ARGENTINA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"CIGB-300","moa":"Casein kinase II (CSNK2)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Laboratorio Elea Phoenix","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Laboratorio Elea Phoenix \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Laboratorio Elea Phoenix \/ Undisclosed"},{"orgOrder":0,"company":"American Regent","sponsor":"CytoDyn","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ CytoDyn","highestDevelopmentStatusID":"9","companyTruncated":"American Regent \/ CytoDyn"},{"orgOrder":0,"company":"National Institutes of Health","sponsor":"CytoDyn","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Collaboration","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institutes of Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institutes of Health \/ CytoDyn","highestDevelopmentStatusID":"9","companyTruncated":"National Institutes of Health \/ CytoDyn"},{"orgOrder":0,"company":"HealthBio, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Maraviroc","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HealthBio, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HealthBio, Inc. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HealthBio, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ZX-7101A","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Zenshine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zenshine Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Zenshine Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ZX-7101A","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Zenshine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zenshine Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Zenshine Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ZX-7101A","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Zenshine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenshine Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Zenshine Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ZX-7101A","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Zenshine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenshine Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Zenshine Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ZX-7101A","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Zenshine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenshine Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Zenshine Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Zenshine Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ZX-7101A","moa":"CEN","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Zenshine Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zenshine Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Zenshine Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"DNDi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Acoziborole","moa":"Cleavage and polyadenylation specificity factor subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ DNDi","highestDevelopmentStatusID":"9","companyTruncated":"Sanofi \/ DNDi"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"rNAPc2","moa":"Coagulation factor VII (F7)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"rNAPc2","moa":"Coagulation factor VII (F7)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"University Medical Center of Johannes Gutenberg University Mainz","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Agreement","leadProduct":"rNAPc2","moa":"Coagulation factor VII (F7)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ University Medical Center of Johannes Gutenberg University Mainz","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ University Medical Center of Johannes Gutenberg University Mainz"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Colorado Prevention Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Recombinant Nematode Anticoagulant Protein c2","moa":"Coagulation factor VII; Tissue factor; Coagulation factor X","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oruka Therapeutics \/ Colorado Prevention Center","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Colorado Prevention Center"},{"orgOrder":0,"company":"Alexion Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"Eculizumab","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Alexion Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alexion Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Alexion Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"InflaRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"InflaRx \/ Undisclosed"},{"orgOrder":0,"company":"InflaRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"InflaRx \/ Undisclosed"},{"orgOrder":0,"company":"InflaRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"InflaRx \/ Undisclosed"},{"orgOrder":0,"company":"InflaRx","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Ifx-1","moa":"Complement C5","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"InflaRx","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InflaRx \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"InflaRx \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"FibroGen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Pamrevlumab","moa":"Connective tissue growth factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"FibroGen","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"FibroGen \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"FibroGen \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Israel Innovation Authority","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Funding","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Israel Innovation Authority","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Israel Innovation Authority"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid, Suspension","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Enlivex Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Allocetra","moa":"CTLA-4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Enlivex Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enlivex Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Enlivex Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Jordan University of Science and Technology","sponsor":"McGill University | InterPharma One","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JORDAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jordan University of Science and Technology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jordan University of Science and Technology \/ McGill University | InterPharma One","highestDevelopmentStatusID":"9","companyTruncated":"Jordan University of Science and Technology \/ McGill University | InterPharma One"},{"orgOrder":0,"company":"AVVA Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CYPRUS","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Clotrimazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AVVA Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suppository","sponsorNew":"AVVA Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AVVA Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ANRS, Emerging Infectious Diseases","sponsor":"CHU Kamenge, BURUNDI | Hospital Avicenne | Institut Pasteur | H\u00f4pital Necker-Enfants Malades | Institut de M\u00e9decine et d'Epid\u00e9miologie Appliqu\u00e9e | H\u00f4pital de Treichville | H\u00f4pital Cocody","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fluconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANRS, Emerging Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANRS, Emerging Infectious Diseases \/ CHU Kamenge, BURUNDI | Hospital Avicenne | Institut Pasteur | H\u00f4pital Necker-Enfants Malades | Institut de M\u00e9decine et d'Epid\u00e9miologie Appliqu\u00e9e | H\u00f4pital de Treichville | H\u00f4pital Cocody","highestDevelopmentStatusID":"9","companyTruncated":"ANRS, Emerging Infectious Diseases \/ CHU Kamenge, BURUNDI | Hospital Avicenne | Institut Pasteur | H\u00f4pital Necker-Enfants Malades | Institut de M\u00e9decine et d'Epid\u00e9miologie Appliqu\u00e9e | H\u00f4pital de Treichville | H\u00f4pital Cocody"},{"orgOrder":0,"company":"Topica Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Luliconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Topica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Topica Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Topica Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Topica Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Luliconazole","moa":"Cytochrome P450 51","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Topica Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Topica Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Topica Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Vidofludimus Calcium","moa":"||DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ European Investment Bank","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ European Investment Bank"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"||DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Altium Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Altium Capital","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Altium Capital"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"University Medical Center Goettingen","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Vidofludimus Calcium","moa":"||DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ University Medical Center Goettingen","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ University Medical Center Goettingen"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vidofludimus Calcium","moa":"DHODH","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunic Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emvododstat","moa":"Dihydroorotate dehydrogenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emvododstat","moa":"Dihydroorotate dehydrogenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Emvododstat","moa":"Dihydroorotate dehydrogenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"PTC Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Emvododstat","moa":"Dihydroorotate dehydrogenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PTC Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"PTC Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"PTC Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Immunic Therapeutics","sponsor":"FGK Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IMU-838","moa":"Dihydroorotate dehydrogenase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Immunic Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Immunic Therapeutics \/ FGK Clinical Research","highestDevelopmentStatusID":"9","companyTruncated":"Immunic Therapeutics \/ FGK Clinical Research"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"NeuroBo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANA Therapeutics \/ NeuroBo Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therapeutics \/ NeuroBo Pharmaceuticals"},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"Quotient Sciences","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANA Therapeutics \/ Quotient Sciences","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therapeutics \/ Quotient Sciences"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"||DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Niclosamide","moa":"||DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NeuroBo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NeuroBo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"ANA Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Niclosamide","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANA Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ANA Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ANA Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Indiana University","sponsor":"Lupin Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Secnidazole","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Indiana University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"Indiana University \/ Lupin Ltd","highestDevelopmentStatusID":"9","companyTruncated":"Indiana University \/ Lupin Ltd"},{"orgOrder":0,"company":"Arrevus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Sodium Fusidate","moa":"Elongation factor G","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Arrevus","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrevus \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Arrevus \/ Undisclosed"},{"orgOrder":0,"company":"Orient Pharma","sponsor":"National Defense Medical Center, Taiwan | NRPB, Taiwan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Isoniazid","moa":"Enoyl-[acyl-carrier-protein] reductase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Orient Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orient Pharma \/ National Defense Medical Center, Taiwan | NRPB, Taiwan","highestDevelopmentStatusID":"9","companyTruncated":"Orient Pharma \/ National Defense Medical Center, Taiwan | NRPB, Taiwan"},{"orgOrder":0,"company":"Tang-Du Hospital","sponsor":"Shenzhen Chipscreen Biosciences | Zhejiang University | First Affiliated Hospital of Guangxi Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Cytotoxic Drug","year":"2016","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Tang-Du Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tang-Du Hospital \/ Shenzhen Chipscreen Biosciences | Zhejiang University | First Affiliated Hospital of Guangxi Medical University","highestDevelopmentStatusID":"9","companyTruncated":"Tang-Du Hospital \/ Shenzhen Chipscreen Biosciences | Zhejiang University | First Affiliated Hospital of Guangxi Medical University"},{"orgOrder":0,"company":"Tang-Du Hospital","sponsor":"Shenzhen Chipscreen Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Cytotoxic Drug","year":"2015","type":"Inapplicable","leadProduct":"Chidamide","moa":"enzyme inhibitors: inhibitors of histone deacetylase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Tang-Du Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tang-Du Hospital \/ Shenzhen Chipscreen Biosciences","highestDevelopmentStatusID":"9","companyTruncated":"Tang-Du Hospital \/ Shenzhen Chipscreen Biosciences"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Upamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Henry M. Jackson Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Funding","leadProduct":"Upamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Henry M. Jackson Foundation","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Henry M. Jackson Foundation"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Upamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Upamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Upamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Upamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"ObvioHealth","sponsor":"RedHill Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Upamostat","moa":"enzyme inhibitors: proteolytic enzyme inhibitors","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ObvioHealth","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ObvioHealth \/ RedHill Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"ObvioHealth \/ RedHill Biopharma"},{"orgOrder":0,"company":"Makerere University","sponsor":"University of Minnesota | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UGANDA","productType":"Cytotoxic Drug","year":"2019","type":"Inapplicable","leadProduct":"Liposomal Amphotericin","moa":"Ergosterol","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Makerere University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Makerere University \/ University of Minnesota | Gilead Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Makerere University \/ University of Minnesota | Gilead Sciences"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen receptor beta","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dompe Farmaceutici \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Dompe Farmaceutici \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"European & Developing Countries Clinical Trials Partnership | Medicines for Malaria Venture | Groupe de Recherche Action en Sante | Institut de Recherche en Sciences de la Sante","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Artemether","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ European & Developing Countries Clinical Trials Partnership | Medicines for Malaria Venture | Groupe de Recherche Action en Sante | Institut de Recherche en Sciences de la Sante","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ European & Developing Countries Clinical Trials Partnership | Medicines for Malaria Venture | Groupe de Recherche Action en Sante | Institut de Recherche en Sciences de la Sante"},{"orgOrder":0,"company":"HaEmek Medical Center, Israel","sponsor":"T MAY BIOPHARMA LTD.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Chloroquine Phosphate","moa":"Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HaEmek Medical Center, Israel","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaEmek Medical Center, Israel \/ T MAY BIOPHARMA LTD.","highestDevelopmentStatusID":"9","companyTruncated":"HaEmek Medical Center, Israel \/ T MAY BIOPHARMA LTD."},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sisunatovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Sisunatovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sisunatovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sisunatovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sisunatovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sisunatovir","moa":"Fusion glycoprotein F0","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"SYMYOO Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Cross Lab Cell \/ SYMYOO Inc","highestDevelopmentStatusID":"9","companyTruncated":"Green Cross Lab Cell \/ SYMYOO Inc"},{"orgOrder":0,"company":"Taw Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Dexamethasone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Taw Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taw Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Taw Pharma \/ Undisclosed"},{"orgOrder":0,"company":"ProFem GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Steroid","year":"2017","type":"Inapplicable","leadProduct":"Fluocinolone Acetonide","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ProFem GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ProFem GmbH \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ProFem GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Post Graduate Institute of Medical Education and Research, Chandigarh","sponsor":"Cipla","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Prednisolone","moa":"Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Post Graduate Institute of Medical Education and Research, Chandigarh","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Post Graduate Institute of Medical Education and Research, Chandigarh \/ Cipla","highestDevelopmentStatusID":"9","companyTruncated":"Post Graduate Institute of Medical Education and Research, Chandigarh \/ Cipla"},{"orgOrder":0,"company":"Ayudas Diagnosticas Sura S.A.S","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"COLOMBIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ivermectin","moa":"Glutamate-gated chloride channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ayudas Diagnosticas Sura S.A.S","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ayudas Diagnosticas Sura S.A.S \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ayudas Diagnosticas Sura S.A.S \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"TJ003234","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kiniksa Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Mavrilimumab","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kiniksa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Kiniksa Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kiniksa Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Nobelpharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Sargramostim","moa":"Granulocyte-macrophage colony-stimulating factor receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Nobelpharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nobelpharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nobelpharma \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"ABX203","moa":"HBsAg","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Pharco Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"EGYPT","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Ravidasvir HCl","moa":"HCV","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pharco Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharco Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pharco Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"ABT-450\/r","moa":"HCV NS3-4A serine protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Chimerix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dociparstat Sodium","moa":"heparin derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Chimerix","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimerix \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Chimerix \/ Undisclosed"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"GC1102","moa":"Hepatitis B surface antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Green Cross Lab Cell \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Green Cross Lab Cell \/ Undisclosed"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"GC1102","moa":"Hepatitis B surface antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Cross Lab Cell \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Green Cross Lab Cell \/ Undisclosed"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"GC1102","moa":"Hepatitis B surface antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Cross Lab Cell \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Green Cross Lab Cell \/ Undisclosed"},{"orgOrder":0,"company":"Green Cross Lab Cell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"GC1102","moa":"Hepatitis B surface antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Green Cross Lab Cell","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Cross Lab Cell \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Green Cross Lab Cell \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Ferrer BioPharma","sponsor":"Hospital CEMESA Cort\u00e9s, San Pedro Sula, Honduras","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Chlorpheniramine Maleate","moa":"Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Dr. Ferrer BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Dr. Ferrer BioPharma \/ Hospital CEMESA Cort\u00e9s, San Pedro Sula, Honduras","highestDevelopmentStatusID":"9","companyTruncated":"Dr. Ferrer BioPharma \/ Hospital CEMESA Cort\u00e9s, San Pedro Sula, Honduras"},{"orgOrder":0,"company":"Dr. Ferrer BioPharma","sponsor":"Hospital CEMESA Cort\u00e9s, San Pedro Sula, Honduras","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Chlorpheniramine Maleate","moa":"Histamine H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Dr. Ferrer BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Dr. Ferrer BioPharma \/ Hospital CEMESA Cort\u00e9s, San Pedro Sula, Honduras","highestDevelopmentStatusID":"9","companyTruncated":"Dr. Ferrer BioPharma \/ Hospital CEMESA Cort\u00e9s, San Pedro Sula, Honduras"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"VM-1500A-LAI","moa":"HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"VM-1500A-LAI","moa":"HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"VM-1500A-LAI","moa":"HIV-1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"VM-1500","moa":"Human immunodeficiency virus Reverse transcriptase (HIV RT)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"VM-1500","moa":"Human immunodeficiency virus Reverse transcriptase (HIV RT)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"VM-1500","moa":"Human immunodeficiency virus Reverse transcriptase (HIV RT)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"Viriom","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"VM-1500","moa":"Human immunodeficiency virus Reverse transcriptase (HIV RT)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Viriom","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Viriom \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Viriom \/ Undisclosed"},{"orgOrder":0,"company":"University of Liverpool","sponsor":"ViiV Healthcare | Makerere University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dolutegravir Sodium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Liverpool","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Liverpool \/ ViiV Healthcare | Makerere University","highestDevelopmentStatusID":"9","companyTruncated":"University of Liverpool \/ ViiV Healthcare | Makerere University"},{"orgOrder":0,"company":"University of Toronto","sponsor":"Unity Health Toronto | Maple Leaf Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Raltegravir Potassium","moa":"Human immunodeficiency virus type 1 integrase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Toronto","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Toronto \/ Unity Health Toronto | Maple Leaf Research","highestDevelopmentStatusID":"9","companyTruncated":"University of Toronto \/ Unity Health Toronto | Maple Leaf Research"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Atazanavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Stanford University","sponsor":"Johnson & Johnson Innovative Medicine | University of Colorado, Denver","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Darunavir","moa":"Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Johnson & Johnson Innovative Medicine | University of Colorado, Denver","highestDevelopmentStatusID":"9","companyTruncated":"Stanford University \/ Johnson & Johnson Innovative Medicine | University of Colorado, Denver"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lopinavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oxford \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"University of Oxford \/ Undisclosed"},{"orgOrder":0,"company":"The HIV Netherlands Australia Thailand Research Collaboration","sponsor":"Radboud University Medical Center | amfAR | PHPT\/AMS Laboratory | Chulalongkorn University | ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Abacavir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"The HIV Netherlands Australia Thailand Research Collaboration","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The HIV Netherlands Australia Thailand Research Collaboration \/ Radboud University Medical Center | amfAR | PHPT\/AMS Laboratory | Chulalongkorn University | ViiV Healthcare","highestDevelopmentStatusID":"9","companyTruncated":"The HIV Netherlands Australia Thailand Research Collaboration \/ Radboud University Medical Center | amfAR | PHPT\/AMS Laboratory | Chulalongkorn University | ViiV Healthcare"},{"orgOrder":0,"company":"Harvard School of Public Health (HSPH)","sponsor":"Ragon Institute of MGH, MIT, Harvard | Brigham and Women's Hospital | Botswana Harvard Health Partnership | University of California, San Diego","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nevirapine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Harvard School of Public Health (HSPH)","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard School of Public Health (HSPH) \/ Ragon Institute of MGH, MIT, Harvard | Brigham and Women's Hospital | Botswana Harvard Health Partnership | University of California, San Diego","highestDevelopmentStatusID":"9","companyTruncated":"Harvard School of Public Health (HSPH) \/ Ragon Institute of MGH, MIT, Harvard | Brigham and Women's Hospital | Botswana Harvard Health Partnership | University of California, San Diego"},{"orgOrder":0,"company":"CAPRISA","sponsor":"CONRAD | Gilead Sciences | FHI 360 | Institute for Healthcare Improvement","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Tenofovir","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"CAPRISA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CAPRISA \/ CONRAD | Gilead Sciences | FHI 360 | Institute for Healthcare Improvement","highestDevelopmentStatusID":"9","companyTruncated":"CAPRISA \/ CONRAD | Gilead Sciences | FHI 360 | Institute for Healthcare Improvement"},{"orgOrder":0,"company":"University of Washington","sponsor":"Kenya Medical Research Institute | University of Colorado, Denver | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tenofovir Alafenamide","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Washington \/ Kenya Medical Research Institute | University of Colorado, Denver | Gilead Sciences","highestDevelopmentStatusID":"9","companyTruncated":"University of Washington \/ Kenya Medical Research Institute | University of Colorado, Denver | Gilead Sciences"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Tenofovir Alafenamide","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Inapplicable","leadProduct":"Ambrisentan","moa":"||IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Evelo Biosciences","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2020","type":"Public Offering","leadProduct":"EDP1815","moa":"IL-6 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evelo Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Evelo Biosciences \/ Morgan Stanley","highestDevelopmentStatusID":"9","companyTruncated":"Evelo Biosciences \/ Morgan Stanley"},{"orgOrder":0,"company":"Statistical Center, NTUHCTC","sponsor":"Taiwan Sugar Cooperation Company","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Probiotic","year":"2016","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Statistical Center, NTUHCTC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Statistical Center, NTUHCTC \/ Taiwan Sugar Cooperation Company","highestDevelopmentStatusID":"9","companyTruncated":"Statistical Center, NTUHCTC \/ Taiwan Sugar Cooperation Company"},{"orgOrder":0,"company":"Rottapharm Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Silymarin","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Rottapharm Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rottapharm Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Rottapharm Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Agennix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Talactoferrin Alfa","moa":"Immune","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Agennix","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Agennix \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Agennix \/ Undisclosed"},{"orgOrder":0,"company":"A. Vogel","sponsor":"Cantonal Hospital of St. Gallen | Labormedizinisches Zentrum Dr. Risch","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Echinacea Purpurea Alcoholic Extract","moa":"Immune system","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"A. Vogel","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"A. Vogel \/ Cantonal Hospital of St. Gallen | Labormedizinisches Zentrum Dr. Risch","highestDevelopmentStatusID":"9","companyTruncated":"A. Vogel \/ Cantonal Hospital of St. Gallen | Labormedizinisches Zentrum Dr. Risch"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"SK Bioscience \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"SK Bioscience \/ AstraZeneca"},{"orgOrder":0,"company":"Gavi","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gavi","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14999999999999999,"dosageForm":"Injection","sponsorNew":"Gavi \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"9","companyTruncated":"Gavi \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Pirbright Institute","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pirbright Institute","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pirbright Institute \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Pirbright Institute \/ Undisclosed"},{"orgOrder":0,"company":"Cobra Biologics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cobra Biologics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cobra Biologics \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Cobra Biologics \/ AstraZeneca"},{"orgOrder":0,"company":"Symbiosis Pharmaceutical Services","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Symbiosis Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Symbiosis Pharmaceutical Services \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Symbiosis Pharmaceutical Services \/ AstraZeneca"},{"orgOrder":0,"company":"Emergent BioSolutions","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Emergent BioSolutions","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.089999999999999997,"dosageForm":"Injection","sponsorNew":"Emergent BioSolutions \/ AstraZeneca","highestDevelopmentStatusID":"9","companyTruncated":"Emergent BioSolutions \/ AstraZeneca"},{"orgOrder":0,"company":"Evgen Pharma","sponsor":"University Of Dundee","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sulforaphane","moa":"||Inactive rhomboid protein 2 (RHBDF2)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evgen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Evgen Pharma \/ University Of Dundee","highestDevelopmentStatusID":"9","companyTruncated":"Evgen Pharma \/ University Of Dundee"},{"orgOrder":0,"company":"FARMAK, a.s","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CZECH REPUBLIC","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Enisamium Iodide","moa":"Influenza virus RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"FARMAK, a.s","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"FARMAK, a.s \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"FARMAK, a.s \/ Undisclosed"},{"orgOrder":0,"company":"BioGeneric Pharma","sponsor":"Xiamen Amoytop Biotech Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Peginterferon Alfa-2a","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioGeneric Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioGeneric Pharma \/ Xiamen Amoytop Biotech Co., Ltd","highestDevelopmentStatusID":"9","companyTruncated":"BioGeneric Pharma \/ Xiamen Amoytop Biotech Co., Ltd"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Interferon Alfa-2B","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Orphan Biovitrum AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Emapalumab","moa":"Interferon gamma","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Swedish Orphan Biovitrum AB","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Swedish Orphan Biovitrum AB \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Swedish Orphan Biovitrum AB \/ Undisclosed"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"QATAR","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Anakinra","moa":"Interleukin-1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucine--tRNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucine--tRNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucine--tRNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucine--tRNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Epetraborole","moa":"Leucine--tRNA ligase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AN2 Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AN2 Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Intsel Chimos","sponsor":"Biophytis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Intsel Chimos","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Intsel Chimos \/ Biophytis","highestDevelopmentStatusID":"9","companyTruncated":"Intsel Chimos \/ Biophytis"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Seqens","sponsor":"Biophytis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Seqens","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seqens \/ Biophytis","highestDevelopmentStatusID":"9","companyTruncated":"Seqens \/ Biophytis"},{"orgOrder":0,"company":"Skyepharma","sponsor":"Biophytis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Partnership","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Skyepharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Skyepharma \/ Biophytis","highestDevelopmentStatusID":"9","companyTruncated":"Skyepharma \/ Biophytis"},{"orgOrder":0,"company":"Biophytis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biophytis \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Biophytis \/ Undisclosed"},{"orgOrder":0,"company":"Foresee Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FP-025","moa":"Matrix metalloproteinase-12 (MMP-12)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Foresee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foresee Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Foresee Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Thirty Respiratory Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RESP301","moa":"Membrane fusion protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Thirty Respiratory Limited","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Thirty Respiratory Limited \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Thirty Respiratory Limited \/ Undisclosed"},{"orgOrder":0,"company":"Thirty Respiratory Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"RESP301","moa":"Membrane fusion protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Thirty Respiratory Limited","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Thirty Respiratory Limited \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Thirty Respiratory Limited \/ Undisclosed"},{"orgOrder":0,"company":"University of Hawaii","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Metformin","moa":"Mitochondrial complex I (NADH dehydrogenase)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Hawaii","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Hawaii \/ Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"University of Hawaii \/ Merck & Co"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bofutrelvir","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Frontier Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Frontier Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"FB2001","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Frontier Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Frontier Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FB2001","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Frontier Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Frontier Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"FB2001","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Frontier Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Frontier Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FB2001","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Frontier Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Frontier Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Frontier Biotechnologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"FB2001","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Frontier Biotechnologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Frontier Biotechnologies \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Frontier Biotechnologies \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SSD8432","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SSD8432","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SSD8432","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Simcere Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ritonavir","moa":"||Mpro","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Simcere Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Simcere Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Simcere Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Chinese University of Hong Kong","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Peramivir","moa":"Neuraminidase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Chinese University of Hong Kong","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chinese University of Hong Kong \/ BioCryst Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Chinese University of Hong Kong \/ BioCryst Pharmaceuticals"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ledipasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Gilead Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Gilead Sciences"},{"orgOrder":0,"company":"Humanity and Health Research Centre","sponsor":"Beijing 302 Hospital | Nanfang Hospital, Southern Medical University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ledipasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Humanity and Health Research Centre","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humanity and Health Research Centre \/ Beijing 302 Hospital | Nanfang Hospital, Southern Medical University","highestDevelopmentStatusID":"9","companyTruncated":"Humanity and Health Research Centre \/ Beijing 302 Hospital | Nanfang Hospital, Southern Medical University"},{"orgOrder":0,"company":"Humanity and Health Research Centre","sponsor":"Beijing 302 Hospital | Gabrail Cancer Center Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Ledipasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Humanity and Health Research Centre","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humanity and Health Research Centre \/ Beijing 302 Hospital | Gabrail Cancer Center Research","highestDevelopmentStatusID":"9","companyTruncated":"Humanity and Health Research Centre \/ Beijing 302 Hospital | Gabrail Cancer Center Research"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ravidasvir","moa":"Nonstructural protein 5A","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ascletis Pharma \/ Undisclosed"},{"orgOrder":0,"company":"London Health Sciences Centre Research Institute (Lawson)","sponsor":"London Health Sciences Centre","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2015","type":"Inapplicable","leadProduct":"Vancomycin Hydrochloride","moa":"Peptidoglycan","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"London Health Sciences Centre Research Institute (Lawson)","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"London Health Sciences Centre Research Institute (Lawson) \/ London Health Sciences Centre","highestDevelopmentStatusID":"9","companyTruncated":"London Health Sciences Centre Research Institute (Lawson) \/ London Health Sciences Centre"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"University Health Network","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ University Health Network","highestDevelopmentStatusID":"9","companyTruncated":"Medicinova \/ University Health Network"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"Pan American Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Primaquine Diphosphate","moa":"Plasmodium Deoxyribonucleic acid (Malaria DNA)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of California, San Francisco \/ Pan American Health Organization","highestDevelopmentStatusID":"9","companyTruncated":"University of California, San Francisco \/ Pan American Health Organization"},{"orgOrder":0,"company":"Bassett Healthcare","sponsor":"Genentech | Viroclinics Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bassett Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bassett Healthcare \/ Genentech | Viroclinics Biosciences","highestDevelopmentStatusID":"9","companyTruncated":"Bassett Healthcare \/ Genentech | Viroclinics Biosciences"},{"orgOrder":0,"company":"Weill Medical College of Cornell University","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Baloxavir Marboxil","moa":"Polymerase acidic protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Weill Medical College of Cornell University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Weill Medical College of Cornell University \/ Genentech","highestDevelopmentStatusID":"9","companyTruncated":"Weill Medical College of Cornell University \/ Genentech"},{"orgOrder":0,"company":"Petrovax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azoximer Bromide","moa":"polymers","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Petrovax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Petrovax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Petrovax \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"GSK | Emergent BioSolutions","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Raxibacumab","moa":"Protective antigen","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"GSK \/ GSK | Emergent BioSolutions","highestDevelopmentStatusID":"9","companyTruncated":"GSK \/ GSK | Emergent BioSolutions"},{"orgOrder":0,"company":"Dermama Biotechnology","sponsor":"Indonesian Ministry of Research and Technology | National Research and Innovation Agency","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Exosome","moa":"PTEN","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Dermama Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dermama Biotechnology \/ Indonesian Ministry of Research and Technology | National Research and Innovation Agency","highestDevelopmentStatusID":"9","companyTruncated":"Dermama Biotechnology \/ Indonesian Ministry of Research and Technology | National Research and Innovation Agency"},{"orgOrder":0,"company":"Laboratorios Roemmers","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ARGENTINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Laboratorios Roemmers","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Roemmers \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Laboratorios Roemmers \/ Undisclosed"},{"orgOrder":0,"company":"R-Pharm","sponsor":"Data Management 365 | K-Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"RPH-104","moa":"receptor molecules","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"R-Pharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"R-Pharm \/ Data Management 365 | K-Research","highestDevelopmentStatusID":"9","companyTruncated":"R-Pharm \/ Data Management 365 | K-Research"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Fosun Pharmaceutical | Henan Genuine Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Azvudine","moa":"Replicase polyprotein 1ab | Reverse transcriptase | Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Fosun Pharmaceutical | Henan Genuine Biotech","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Henlius Biotech \/ Fosun Pharmaceutical | Henan Genuine Biotech"},{"orgOrder":0,"company":"Shanghai Henlius Biotech","sponsor":"Huashan Hospital | Fosun Pharmaceutical | Henan Genuine Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Azvudine","moa":"Replicase polyprotein 1ab | Reverse transcriptase | Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Shanghai Henlius Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Henlius Biotech \/ Huashan Hospital | Fosun Pharmaceutical | Henan Genuine Biotech","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai Henlius Biotech \/ Huashan Hospital | Fosun Pharmaceutical | Henan Genuine Biotech"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"LAU-7b","moa":"Retinoic acid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laurent Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Laurent Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"LAU-7b","moa":"Retinoic acid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laurent Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Laurent Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Laurent Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Laurent Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Laurent Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Laurent Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Peschke","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Riboflavin","moa":"Riboflavin kinase; Riboflavin synthase; Flavin reductase (NADPH)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peschke","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Peschke \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peschke \/ Undisclosed"},{"orgOrder":0,"company":"Irrua Specialist Teaching Hospital","sponsor":"Alliance for International Medical Action | University of Bordeaux | Bernhard Nocht Institute for Tropical Medicine | Federal Medical Centre, Owo | Programme PAC-CI | Fondation Recherche Scientifique Benin | M\u00e9decins Sans Fronti\u00e8res Belgium | Alex Ekwueme","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NIGERIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Irrua Specialist Teaching Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Irrua Specialist Teaching Hospital \/ Alliance for International Medical Action | University of Bordeaux | Bernhard Nocht Institute for Tropical Medicine | Federal Medical Centre, Owo | Programme PAC-CI | Fondation Recherche Scientifique Benin | M\u00e9decins Sans Fronti\u00e8res Belgium | Alex Ekwueme","highestDevelopmentStatusID":"9","companyTruncated":"Irrua Specialist Teaching Hospital \/ Alliance for International Medical Action | University of Bordeaux | Bernhard Nocht Institute for Tropical Medicine | Federal Medical Centre, Owo | Programme PAC-CI | Fondation Recherche Scientifique Benin | M\u00e9decins Sans Fronti\u00e8res Belgium | Alex Ekwueme"},{"orgOrder":0,"company":"Scientific and Technological Research Council of Turkey","sponsor":"Ankara City Hospital Bilkent | Istanbul Umraniye Training and Research Hospital | Ko\u00e7 University | Monitor CRO","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ribavirin","moa":"RNA | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Inosine-5'-monophosphate dehydrogenase 1","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Scientific and Technological Research Council of Turkey","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Scientific and Technological Research Council of Turkey \/ Ankara City Hospital Bilkent | Istanbul Umraniye Training and Research Hospital | Ko\u00e7 University | Monitor CRO","highestDevelopmentStatusID":"9","companyTruncated":"Scientific and Technological Research Council of Turkey \/ Ankara City Hospital Bilkent | Istanbul Umraniye Training and Research Hospital | Ko\u00e7 University | Monitor CRO"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Russian Direct Investment Fund \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Russian Direct Investment Fund \/ Undisclosed"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Russian Direct Investment Fund","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Russian Direct Investment Fund \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Russian Direct Investment Fund \/ Undisclosed"},{"orgOrder":0,"company":"Chromis","sponsor":"Chemical Diversity Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Favipiravir","moa":"RNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Chromis","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chromis \/ Chemical Diversity Research Institute","highestDevelopmentStatusID":"9","companyTruncated":"Chromis \/ Chemical Diversity Research Institute"},{"orgOrder":0,"company":"Professor Dr. Bernd M\u00fchlbauer","sponsor":"INSERM | World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Remdesivir","moa":"RNA-directed RNA polymerase L | Replicase polyprotein 1ab","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Professor Dr. Bernd M\u00fchlbauer","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Professor Dr. Bernd M\u00fchlbauer \/ INSERM | World Health Organization","highestDevelopmentStatusID":"9","companyTruncated":"Professor Dr. Bernd M\u00fchlbauer \/ INSERM | World Health Organization"},{"orgOrder":0,"company":"University of Ibadan","sponsor":"Shin Poong Pharm Co Ltd | Institute for Advanced Medical Research and Training, University of Ibadan, Ibadan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"NIGERIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pyronaridine","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase (ATP2A)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Ibadan","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Granules","sponsorNew":"University of Ibadan \/ Shin Poong Pharm Co Ltd | Institute for Advanced Medical Research and Training, University of Ibadan, Ibadan","highestDevelopmentStatusID":"9","companyTruncated":"University of Ibadan \/ Shin Poong Pharm Co Ltd | Institute for Advanced Medical Research and Training, University of Ibadan, Ibadan"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Pyronaridine","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase (ATP2A)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shin Poong Pharm Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Shin Poong Pharm Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Shin Poong Pharm Co Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Pyronaridine","moa":"Sarcoplasmic\/endoplasmic reticulum calcium ATPase (ATP2A)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Shin Poong Pharm Co Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shin Poong Pharm Co Ltd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Shin Poong Pharm Co Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Nortec Quimica","sponsor":"The Medicines Patent Pool","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Nirmatrelvir","moa":"||SARS coronavirus 3C-like proteinase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Nortec Quimica","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nortec Quimica \/ The Medicines Patent Pool","highestDevelopmentStatusID":"9","companyTruncated":"Nortec Quimica \/ The Medicines Patent Pool"},{"orgOrder":0,"company":"Gennova Biopharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gennova Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gennova Biopharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Gennova Biopharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Medicago","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medicago \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Medicago \/ Undisclosed"},{"orgOrder":0,"company":"Medicago","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COVID-19 Vaccine","moa":"SARS-CoV-2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Medicago","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medicago \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Medicago \/ Undisclosed"},{"orgOrder":0,"company":"Genencell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"ES16001","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Genencell","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genencell \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Genencell \/ Undisclosed"},{"orgOrder":0,"company":"Genencell","sponsor":"Ordi Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Plant Extract\/Herbal","year":"2022","type":"Agreement","leadProduct":"ES16001","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Genencell","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genencell \/ Ordi Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Genencell \/ Ordi Pharma"},{"orgOrder":0,"company":"Shanghai JunTop Biosciences Co., LTD","sponsor":"Sponsor GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JT001","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Shanghai JunTop Biosciences Co., LTD","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Shanghai JunTop Biosciences Co., LTD \/ Sponsor GmbH","highestDevelopmentStatusID":"9","companyTruncated":"Shanghai JunTop Biosciences Co., LTD \/ Sponsor GmbH"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Vesicular Stomatitis Virus Delta G","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"NRx Pharmaceuticals \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Israel Institute for Biological Research"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Vesicular Stomatitis Virus Delta G","moa":"SARS-CoV-2 replication","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"NRx Pharmaceuticals \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Israel Institute for Biological Research"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SCTA01","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SCTA01","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SCTA01","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"SCTA01","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Sinocelltech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"SCTA01","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sinocelltech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinocelltech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sinocelltech \/ Undisclosed"},{"orgOrder":0,"company":"Abpro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ABP 300","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abpro \/ Undisclosed"},{"orgOrder":0,"company":"Abpro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ABP 300","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abpro \/ Undisclosed"},{"orgOrder":0,"company":"Abpro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ABP 300","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Abpro","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abpro \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Abpro \/ Undisclosed"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"University Medical Centre Groningen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ University Medical Centre Groningen","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ University Medical Centre Groningen"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Stelis Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Termination","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ Stelis Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Stelis Biopharma"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"University Medical Center Groningen","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ University Medical Center Groningen","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ University Medical Center Groningen"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Biolexis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ Biolexis","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Biolexis"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Akston Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"AKS-452","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Akston Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akston Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Akston Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Biological E","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"BECOV2D","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dynavax Technologies \/ Biological E","highestDevelopmentStatusID":"9","companyTruncated":"Dynavax Technologies \/ Biological E"},{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BNT162","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Fosun Pharmaceutical \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Fosun Pharmaceutical \/ BioNTech"},{"orgOrder":0,"company":"Sinopharm","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sinopharm \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Sinopharm \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Jacobson Pharma","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"BNT162","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jacobson Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jacobson Pharma \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"Jacobson Pharma \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"Rentschler Biopharma","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Rentschler Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rentschler Biopharma \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Rentschler Biopharma \/ BioNTech"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2020","type":"Acquisition","leadProduct":"BNT162","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"BioNTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BNT162","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ BioNTech","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ BioNTech"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"UK Governement","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Agreement","leadProduct":"BNT162","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pfizer Inc \/ UK Governement","highestDevelopmentStatusID":"9","companyTruncated":"Pfizer Inc \/ UK Governement"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"BNT162b5","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"Xencor","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"C-135-LS","moa":"||SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Xencor","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xencor \/ Bristol Myers Squibb","highestDevelopmentStatusID":"9","companyTruncated":"Xencor \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COVID-19 Vaccine Recombinant","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yisheng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Yisheng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"CureVac","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Cvncov","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"CureVac","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"CureVac \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"CureVac \/ Undisclosed"},{"orgOrder":0,"company":"ReiThera","sponsor":"Spallanzani Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GRAd-COV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ReiThera","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReiThera \/ Spallanzani Institute","highestDevelopmentStatusID":"9","companyTruncated":"ReiThera \/ Spallanzani Institute"},{"orgOrder":0,"company":"ReiThera","sponsor":"Spallanzani Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GRAd-COV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ReiThera","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReiThera \/ Spallanzani Institute","highestDevelopmentStatusID":"9","companyTruncated":"ReiThera \/ Spallanzani Institute"},{"orgOrder":0,"company":"ReiThera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"GRAd-COV2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ReiThera","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReiThera \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ReiThera \/ Undisclosed"},{"orgOrder":0,"company":"Genexine","sponsor":"PT Kalbe Farma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"GX-19N","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Genexine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genexine \/ PT Kalbe Farma","highestDevelopmentStatusID":"9","companyTruncated":"Genexine \/ PT Kalbe Farma"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Rainier Clinical Research Center | C3 Research Associates","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Rainier Clinical Research Center | C3 Research Associates","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Rainier Clinical Research Center | C3 Research Associates"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Gennova Biopharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Gennova Biopharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Gennova Biopharmaceuticals"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Undisclosed"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Undisclosed"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"National Institute Of Allergy And Infectious Diseases.","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ National Institute Of Allergy And Infectious Diseases.","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ National Institute Of Allergy And Infectious Diseases."},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Zoic Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Financing","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Zoic Capital","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Zoic Capital"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Quratis Co., Ltd","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Quratis Co., Ltd","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Quratis Co., Ltd"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Undisclosed"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Quratis Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Quratis Co., Ltd","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Quratis Co., Ltd"},{"orgOrder":0,"company":"HDT Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"HDT-301","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HDT Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HDT Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HDT Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Beijing Advaccine Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Beijing Advaccine Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Beijing Advaccine Biotechnology"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Richter-Helm BioLogics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Richter-Helm BioLogics","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Richter-Helm BioLogics"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"The International Vaccine Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Partnership","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ The International Vaccine Institute","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ The International Vaccine Institute"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Public Offering","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"US Department of Defense","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ US Department of Defense","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ US Department of Defense"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ CEPI","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ CEPI"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ CEPI","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ CEPI"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Beijing Advaccine Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inovio Pharmaceuticals \/ Beijing Advaccine Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Beijing Advaccine Biotechnology"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Coalition for Epidemic Preparedness Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Coalition for Epidemic Preparedness Innovations"},{"orgOrder":0,"company":"Inovio Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"INO-4800","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inovio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inovio Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inovio Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"mRNA-1273.211","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.211","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PIKA COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yisheng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Yisheng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"PIKA COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yisheng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Yisheng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"PIKA COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yisheng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Yisheng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Yisheng Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PIKA COVID-19 Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Yisheng Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yisheng Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Yisheng Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Protein COVID-19 Vaccine Recombinant","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Recbio Technology \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Recbio Technology \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recov","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Recbio Technology \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Recbio Technology \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recov","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Recbio Technology \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Recbio Technology \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recov","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Recbio Technology \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Recbio Technology \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Recbio Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Recov","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Recbio Technology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Recbio Technology \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Recbio Technology \/ Undisclosed"},{"orgOrder":0,"company":"BioNTech","sponsor":"Fosun Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Fosun Pharmaceutical","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/ Fosun Pharmaceutical"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"BNT162b2","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"Xenothera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"XAV-19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Xenothera","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xenothera \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Xenothera \/ Undisclosed"},{"orgOrder":0,"company":"Xenothera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"XAV-19","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Xenothera","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Xenothera \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Xenothera \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BI767551","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"BI767551","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"hAd5-S-Fusion","moa":"SARS-CoV-2 Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"ImmunityBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"hAd5-S-Fusion","moa":"SARS-CoV-2 Spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ImmunityBio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"ImmunityBio \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"ImmunityBio \/ Undisclosed"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"NmCV-5","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Serum Institute of India \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Serum Institute of India \/ Undisclosed"},{"orgOrder":0,"company":"Berlin Cures","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"Rovunaptabin","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Berlin Cures","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Berlin Cures \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Berlin Cures \/ Undisclosed"},{"orgOrder":0,"company":"Dynavax Technologies","sponsor":"Clover Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"5QB0T2IUN0","moa":"||SARS-CoV-2 S-trimer","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Dynavax Technologies","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dynavax Technologies \/ Clover Biopharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Dynavax Technologies \/ Clover Biopharmaceuticals"},{"orgOrder":0,"company":"INMUNOVA","sponsor":"Exeltis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ARGENTINA","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"INM004","moa":"Shiga Toxin","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"INMUNOVA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"INMUNOVA \/ Exeltis","highestDevelopmentStatusID":"9","companyTruncated":"INMUNOVA \/ Exeltis"},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Sialidase L","moa":"Sialic acid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ansun Biopharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"Sialidase L","moa":"Sialic acid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ansun Biopharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"Ansun Biopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Inapplicable","leadProduct":"DAS181","moa":"Sialoglycans | Glycosaminoglycans","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ansun Biopharm","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ansun Biopharm \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Ansun Biopharm \/ Undisclosed"},{"orgOrder":0,"company":"HK Surgical","sponsor":"University of California, Riverside","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Tumescent Anesthesia","moa":"Sodium channel","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HK Surgical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HK Surgical \/ University of California, Riverside","highestDevelopmentStatusID":"9","companyTruncated":"HK Surgical \/ University of California, Riverside"},{"orgOrder":0,"company":"Mundipharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Mundipharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Patch","sponsorNew":"Mundipharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Mundipharma \/ Undisclosed"},{"orgOrder":0,"company":"Cambridge University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapagliflozin","moa":"||Sodium\/glucose cotransporter 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cambridge University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cambridge University \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Cambridge University \/ Undisclosed"},{"orgOrder":0,"company":"Cosmo Pharmaceuticals","sponsor":"RedHill Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cosmo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Cosmo Pharmaceuticals \/ RedHill Biopharma","highestDevelopmentStatusID":"9","companyTruncated":"Cosmo Pharmaceuticals \/ RedHill Biopharma"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Kukbo Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Private Placement","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Kukbo Co","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Kukbo Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"State Of Pennsylvania","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ State Of Pennsylvania","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ State Of Pennsylvania"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Kukbo Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0.01,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Kukbo Co","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Kukbo Co"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Partnership","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"RedHill Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Opaganib","moa":"||Sphingosine kinase 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"RedHill Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RedHill Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"RedHill Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ADG20","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ADG20","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Series B Financing","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Google Ventures","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Google Ventures"},{"orgOrder":0,"company":"Invivyd","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Partnership","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Biocon","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Biocon"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Invivyd \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ Undisclosed"},{"orgOrder":0,"company":"Invivyd","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Series C Financing","leadProduct":"Adintrevimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Invivyd","amount2":0.34000000000000002,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.34000000000000002,"dosageForm":"Injection","sponsorNew":"Invivyd \/ RA Capital Management","highestDevelopmentStatusID":"9","companyTruncated":"Invivyd \/ RA Capital Management"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Eli Lilly | Advancing Clinical Therapeutics Globally | Brii Biosciences | AstraZeneca | Sagent Pharmaceuticals | Synairgen | Bristol Myers Squibb | SAB Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Eli Lilly | Advancing Clinical Therapeutics Globally | Brii Biosciences | AstraZeneca | Sagent Pharmaceuticals | Synairgen | Bristol Myers Squibb | SAB Biotherapeutics","highestDevelopmentStatusID":"9","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Eli Lilly | Advancing Clinical Therapeutics Globally | Brii Biosciences | AstraZeneca | Sagent Pharmaceuticals | Synairgen | Bristol Myers Squibb | SAB Biotherapeutics"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"AbCellera","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Bamlanivimab","moa":"||Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ AbCellera","highestDevelopmentStatusID":"9","companyTruncated":"Regeneron Pharmaceuticals \/ AbCellera"},{"orgOrder":0,"company":"BioNTech","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BNT162b1","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNTech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNTech \/ Pfizer Inc","highestDevelopmentStatusID":"9","companyTruncated":"BioNTech \/ Pfizer Inc"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Celltrion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CT-P59","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Celltrion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Celltrion \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Molecular Partners","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ensovibep","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Molecular Partners","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Molecular Partners"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Molecular Partners","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Ensovibep","moa":"||Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Molecular Partners","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Molecular Partners"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Molecular Partners","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Ensovibep","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Molecular Partners","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Molecular Partners"},{"orgOrder":0,"company":"Cambridge University Hospitals NHS Foundation Trust","sponsor":"Life Arc | Kidney Research UK | Union Therapeutics | Addenbrookes Charitable Trust | GSK | National Institute for Health Research, UK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Sotrovimab","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Cambridge University Hospitals NHS Foundation Trust","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cambridge University Hospitals NHS Foundation Trust \/ Life Arc | Kidney Research UK | Union Therapeutics | Addenbrookes Charitable Trust | GSK | National Institute for Health Research, UK","highestDevelopmentStatusID":"9","companyTruncated":"Cambridge University Hospitals NHS Foundation Trust \/ Life Arc | Kidney Research UK | Union Therapeutics | Addenbrookes Charitable Trust | GSK | National Institute for Health Research, UK"},{"orgOrder":0,"company":"GSK","sponsor":"Vir Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"VIR-7831","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GSK \/ Vir Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"GSK \/ Vir Biotechnology"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"VIR-7831","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vir Biotechnology \/ GSK","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotechnology \/ GSK"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"VIR-7831","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vir Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"VIR-7831","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vir Biotechnology \/ GSK","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotechnology \/ GSK"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"VIR-7831","moa":"Spike glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vir Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Vir Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Wolfson Medical Center","sponsor":"Assaf-Harofeh Medical Center | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Alirocumab","moa":"Subtilisin\/kexin type 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Wolfson Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wolfson Medical Center \/ Assaf-Harofeh Medical Center | Sanofi","highestDevelopmentStatusID":"9","companyTruncated":"Wolfson Medical Center \/ Assaf-Harofeh Medical Center | Sanofi"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Human Immune Monitoring Center at Stanford University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Human Immune Monitoring Center at Stanford University","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Human Immune Monitoring Center at Stanford University"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ National Institutes of Health","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ National Institutes of Health"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Stanford University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Stanford University","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Stanford University"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Galveston National Laboratory","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Galveston National Laboratory","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Galveston National Laboratory"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Adamis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tempol","moa":"Superoxide dismutase Cu-Zn (SOD Cu-Zn)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Adamis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adamis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Adamis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kare Biosciences","sponsor":"JSS Medical Research | Biomedical Advanced Research and Development Authority | Open Philanthropy | Charak Laboratories | Charak Foundation | Biolink LifeSciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ramatroban","moa":"Thromboxane A2 receptor | G protein-coupled receptor 44","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kare Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kare Biosciences \/ JSS Medical Research | Biomedical Advanced Research and Development Authority | Open Philanthropy | Charak Laboratories | Charak Foundation | Biolink LifeSciences","highestDevelopmentStatusID":"9","companyTruncated":"Kare Biosciences \/ JSS Medical Research | Biomedical Advanced Research and Development Authority | Open Philanthropy | Charak Laboratories | Charak Foundation | Biolink LifeSciences"},{"orgOrder":0,"company":"Biolink LifeSciences","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Funding","leadProduct":"Ramatroban","moa":"Thromboxane A2 receptor | G protein-coupled receptor 44","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biolink LifeSciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolink LifeSciences \/ BARDA","highestDevelopmentStatusID":"9","companyTruncated":"Biolink LifeSciences \/ BARDA"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Oruka Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"AB-201","moa":"Tissue factor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Oruka Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Oruka Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Oruka Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Alteplase","moa":"Tissue-type plasminogen activator","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Edesa Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Edesa Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Edesa Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Edesa Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Edesa Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Edesa Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Paridiprubart","moa":"TLR4","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Edesa Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ Undisclosed"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"INmune Bio \/ Undisclosed"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"INmune Bio \/ Undisclosed"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Beijing Defengrui Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Beijing Defengrui Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Beijing Defengrui Biotechnology"},{"orgOrder":0,"company":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","sponsor":"Beijing Defengrui Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"BDB001","moa":"Toll-like receptor (TLR)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Staidson (Beijing) Biopharmaceuticals Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Beijing Defengrui Biotechnology","highestDevelopmentStatusID":"9","companyTruncated":"Staidson (Beijing) Biopharmaceuticals Co., Ltd \/ Beijing Defengrui Biotechnology"},{"orgOrder":0,"company":"ScandiBio Therapeutics","sponsor":"Istanbul Medipol University Hospital | Istanbul Umraniye Training and Research Hospital | Bakirkoy Dr. Sadi Konuk Research and Training Hospital | Dr. Lutfi Kirdar Kartal Training and Research Hospital | Bagcilar Training and Research Hospital | Kanuni Su","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ScandiBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ScandiBio Therapeutics \/ Istanbul Medipol University Hospital | Istanbul Umraniye Training and Research Hospital | Bakirkoy Dr. Sadi Konuk Research and Training Hospital | Dr. Lutfi Kirdar Kartal Training and Research Hospital | Bagcilar Training and Research Hospital | Kanuni Su","highestDevelopmentStatusID":"9","companyTruncated":"ScandiBio Therapeutics \/ Istanbul Medipol University Hospital | Istanbul Umraniye Training and Research Hospital | Bakirkoy Dr. Sadi Konuk Research and Training Hospital | Dr. Lutfi Kirdar Kartal Training and Research Hospital | Bagcilar Training and Research Hospital | Kanuni Su"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"QATAR","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Hamad Medical Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"QATAR","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Hamad Medical Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Hamad Medical Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Hamad Medical Corporation \/ Undisclosed"},{"orgOrder":0,"company":"University of Cologne","sponsor":"Apogenix","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Cologne","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Cologne \/ Apogenix","highestDevelopmentStatusID":"9","companyTruncated":"University of Cologne \/ Apogenix"},{"orgOrder":0,"company":"Columbia University Irving Medical Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Columbia University Irving Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia University Irving Medical Center \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Columbia University Irving Medical Center \/ Undisclosed"},{"orgOrder":0,"company":"IQVIA","sponsor":"Walter And Eliza Hall Institute Of Medical Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9 | Toll-like receptor 7 | Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"IQVIA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IQVIA \/ Walter And Eliza Hall Institute Of Medical Research","highestDevelopmentStatusID":"9","companyTruncated":"IQVIA \/ Walter And Eliza Hall Institute Of Medical Research"},{"orgOrder":0,"company":"Edesa Biotech","sponsor":"JSS Medical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"EB05","moa":"Toll-like-4 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Edesa Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Edesa Biotech \/ JSS Medical Research","highestDevelopmentStatusID":"9","companyTruncated":"Edesa Biotech \/ JSS Medical Research"},{"orgOrder":0,"company":"Barcelona Institute for Global Health","sponsor":"Leiden University Medical Center | Bahir Dar University | Centro de Investigacao em Saude de Manhica | London School of Hygiene & Tropical Medicine | Kenya Medical Research Institute | Laboratorios Liconsa | Universidad de Le\u00f3n | European & Developing Cou","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Albendazole","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Barcelona Institute for Global Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Barcelona Institute for Global Health \/ Leiden University Medical Center | Bahir Dar University | Centro de Investigacao em Saude de Manhica | London School of Hygiene & Tropical Medicine | Kenya Medical Research Institute | Laboratorios Liconsa | Universidad de Le\u00f3n | European & Developing Cou","highestDevelopmentStatusID":"9","companyTruncated":"Barcelona Institute for Global Health \/ Leiden University Medical Center | Bahir Dar University | Centro de Investigacao em Saude de Manhica | London School of Hygiene & Tropical Medicine | Kenya Medical Research Institute | Laboratorios Liconsa | Universidad de Le\u00f3n | European & Developing Cou"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Oxford \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"University of Oxford \/ Undisclosed"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Colchicine","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Oxford \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"University of Oxford \/ Undisclosed"},{"orgOrder":0,"company":"Universidad Peruana Cayetano Heredia","sponsor":"Oxfendazole Development Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"PERU","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fenbendazole","moa":"Tubulin","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Universidad Peruana Cayetano Heredia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Universidad Peruana Cayetano Heredia \/ Oxfendazole Development Group","highestDevelopmentStatusID":"9","companyTruncated":"Universidad Peruana Cayetano Heredia \/ Oxfendazole Development Group"},{"orgOrder":0,"company":"INmune Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"INB03","moa":"Tumor necrosis factor (TNF)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"INmune Bio \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"INmune Bio \/ Undisclosed"},{"orgOrder":0,"company":"Bassett Healthcare","sponsor":"Reid Health | Goshen Health System","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Losartan Potassium","moa":"Type-1 angiotensin II receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bassett Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bassett Healthcare \/ Reid Health | Goshen Health System","highestDevelopmentStatusID":"9","companyTruncated":"Bassett Healthcare \/ Reid Health | Goshen Health System"},{"orgOrder":0,"company":"Nanjing Sanhome Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"SH229","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Nanjing Sanhome Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Nanjing Sanhome Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nanjing Sanhome Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University of S\u00e3o Paulo General Hospital","sponsor":"D'Antonio Consultants International, Inc. | Sao Paulo, Secretaria de Estado da Sa\u00fade","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"2012 Trivalent Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of S\u00e3o Paulo General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of S\u00e3o Paulo General Hospital \/ D'Antonio Consultants International, Inc. | Sao Paulo, Secretaria de Estado da Sa\u00fade","highestDevelopmentStatusID":"9","companyTruncated":"University of S\u00e3o Paulo General Hospital \/ D'Antonio Consultants International, Inc. | Sao Paulo, Secretaria de Estado da Sa\u00fade"},{"orgOrder":0,"company":"ANRS, Emerging Infectious Diseases","sponsor":"European & Developing Countries Clinical Trials Partnership | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI | Ministry of Health, Rwanda | INSERM | Universi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"ABC-3TC-EFV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ANRS, Emerging Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ANRS, Emerging Infectious Diseases \/ European & Developing Countries Clinical Trials Partnership | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI | Ministry of Health, Rwanda | INSERM | Universi","highestDevelopmentStatusID":"9","companyTruncated":"ANRS, Emerging Infectious Diseases \/ European & Developing Countries Clinical Trials Partnership | Public Research Centre Health, Luxembourg | Ministry of Foreign Affairs, Luxembourg | University of Ouagadougou, Burkina Faso | Programme PAC-CI | Ministry of Health, Rwanda | INSERM | Universi"},{"orgOrder":0,"company":"Suzhou Abogen Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ABO1020","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Suzhou Abogen Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Abogen Biosciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Suzhou Abogen Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Advagene Biopharma","sponsor":"Gadjah Mada University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"AD17002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Advagene Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advagene Biopharma \/ Gadjah Mada University","highestDevelopmentStatusID":"9","companyTruncated":"Advagene Biopharma \/ Gadjah Mada University"},{"orgOrder":0,"company":"Advagene Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AD17002","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Advagene Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Advagene Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Advagene Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"GCAM Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"Adacel","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"GCAM Inc.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GCAM Inc. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"GCAM Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Herbal Institute AB","sponsor":"National Family Medicine Training Centre, Georgia | Tbilisi State Medical University | Phytomed AB","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Dietary Supplement","year":"2021","type":"Inapplicable","leadProduct":"ADAPT-232","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Swedish Herbal Institute AB","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swedish Herbal Institute AB \/ National Family Medicine Training Centre, Georgia | Tbilisi State Medical University | Phytomed AB","highestDevelopmentStatusID":"9","companyTruncated":"Swedish Herbal Institute AB \/ National Family Medicine Training Centre, Georgia | Tbilisi State Medical University | Phytomed AB"},{"orgOrder":0,"company":"Seqirus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Adjuvanted SARS-CoV-2 Subunit Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Seqirus","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seqirus \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Seqirus \/ Undisclosed"},{"orgOrder":0,"company":"Resilience Government Services","sponsor":"Enabling Biotechnologies","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"ADM-03820","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Resilience Government Services","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resilience Government Services \/ Enabling Biotechnologies","highestDevelopmentStatusID":"9","companyTruncated":"Resilience Government Services \/ Enabling Biotechnologies"},{"orgOrder":0,"company":"AnGes","sponsor":"Japan Agency for Medical Research and Development","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AG0302-COVID19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnGes \/ Japan Agency for Medical Research and Development","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Japan Agency for Medical Research and Development"},{"orgOrder":0,"company":"AnGes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AG0302-COVID19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnGes \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Undisclosed"},{"orgOrder":0,"company":"AnGes","sponsor":"Japan Agency for Medical Research and Development","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"AG0302-COVID19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnGes \/ Japan Agency for Medical Research and Development","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Japan Agency for Medical Research and Development"},{"orgOrder":0,"company":"AnGes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AG0302-COVID-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnGes \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Undisclosed"},{"orgOrder":0,"company":"AnGes","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"AG0302-COVID-19","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AnGes","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"AnGes \/ Fresh Tracks Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"AnGes \/ Fresh Tracks Therapeutics"},{"orgOrder":0,"company":"Indonesian Ministry of Research and Technology","sponsor":"Dr. Moewardi General Hospital, Surakarta, Indonesia | Dr. Sardjito General Hospital, Yogyakarta, Indonesia | Dr. Hasan Sadikin General Hospital, Bandung, Indonesia | Bifarma Adiluhung","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"Allogenic Umbilical Cord Mesenchymal Stem Cell","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Indonesian Ministry of Research and Technology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Indonesian Ministry of Research and Technology \/ Dr. Moewardi General Hospital, Surakarta, Indonesia | Dr. Sardjito General Hospital, Yogyakarta, Indonesia | Dr. Hasan Sadikin General Hospital, Bandung, Indonesia | Bifarma Adiluhung","highestDevelopmentStatusID":"9","companyTruncated":"Indonesian Ministry of Research and Technology \/ Dr. Moewardi General Hospital, Surakarta, Indonesia | Dr. Sardjito General Hospital, Yogyakarta, Indonesia | Dr. Hasan Sadikin General Hospital, Bandung, Indonesia | Bifarma Adiluhung"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"HIV Vaccine Trials Network | Bill & Melinda Gates Foundation | Medical Research Council | Sanofi | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Alvac-Hiv","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ HIV Vaccine Trials Network | Bill & Melinda Gates Foundation | Medical Research Council | Sanofi | GSK","highestDevelopmentStatusID":"9","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ HIV Vaccine Trials Network | Bill & Melinda Gates Foundation | Medical Research Council | Sanofi | GSK"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"HIV Vaccine Trials Network | Sanofi | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Alvac-Hiv","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ HIV Vaccine Trials Network | Sanofi | GSK","highestDevelopmentStatusID":"9","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ HIV Vaccine Trials Network | Sanofi | GSK"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Sanofi | GSK | Bill & Melinda Gates Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Alvac-Hiv","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Sanofi | GSK | Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"9","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Sanofi | GSK | Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"GSK | Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Alvac-Hiv","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ GSK | Sanofi","highestDevelopmentStatusID":"9","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ GSK | Sanofi"},{"orgOrder":0,"company":"Avi-Mex","sponsor":"National Council of Science and Technology, Mexico | Instituto Nacional de Enfermedades Respiratorias","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MEXICO","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"AVX-COVID\/12","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Avi-Mex","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avi-Mex \/ National Council of Science and Technology, Mexico | Instituto Nacional de Enfermedades Respiratorias","highestDevelopmentStatusID":"9","companyTruncated":"Avi-Mex \/ National Council of Science and Technology, Mexico | Instituto Nacional de Enfermedades Respiratorias"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AZD5156","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"The International Vaccine Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Aluminium Hydroxide","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bharat Biotech \/ The International Vaccine Institute","highestDevelopmentStatusID":"9","companyTruncated":"Bharat Biotech \/ The International Vaccine Institute"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"BBV87","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Bharat Biotech \/ Undisclosed"},{"orgOrder":0,"company":"D'Or Institute for Research and Education","sponsor":"Apis Flora Industrial e Comercial Ltda","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BRAZIL","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Brazilian Green Propolis Extract","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"D'Or Institute for Research and Education","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"D'Or Institute for Research and Education \/ Apis Flora Industrial e Comercial Ltda","highestDevelopmentStatusID":"9","companyTruncated":"D'Or Institute for Research and Education \/ Apis Flora Industrial e Comercial Ltda"},{"orgOrder":0,"company":"NovaBay Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"CD07223","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NovaBay Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NovaBay Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NovaBay Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"CIC Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CIC Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"Clover Biopharmaceuticals","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"AS03","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Clover Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clover Biopharmaceuticals \/ GSK","highestDevelopmentStatusID":"9","companyTruncated":"Clover Biopharmaceuticals \/ GSK"},{"orgOrder":0,"company":"MICROGEN","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"COVID-globulin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"MICROGEN","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"MICROGEN \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"MICROGEN \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"DTwP-HepB-IPV-Hib Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"National Center for Advancing Translational Sciences","sponsor":"Acer Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Emetine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"National Center for Advancing Translational Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"National Center for Advancing Translational Sciences \/ Acer Therapeutics","highestDevelopmentStatusID":"9","companyTruncated":"National Center for Advancing Translational Sciences \/ Acer Therapeutics"},{"orgOrder":0,"company":"Eskisehir Osmangazi University","sponsor":"Abdi Ibrahim","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TURKEY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"EPs 7630","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Eskisehir Osmangazi University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eskisehir Osmangazi University \/ Abdi Ibrahim","highestDevelopmentStatusID":"9","companyTruncated":"Eskisehir Osmangazi University \/ Abdi Ibrahim"},{"orgOrder":0,"company":"Evofem Biosciences","sponsor":"Clinical Research Management","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"EVO100","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Evofem Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evofem Biosciences \/ Clinical Research Management","highestDevelopmentStatusID":"9","companyTruncated":"Evofem Biosciences \/ Clinical Research Management"},{"orgOrder":0,"company":"Queen Elizabeth II Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Probiotic","year":"2016","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Queen Elizabeth II Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Enema","sponsorNew":"Queen Elizabeth II Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Queen Elizabeth II Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Formic Acid","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Rambam Health Care Campus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Formic Acid","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Rambam Health Care Campus","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rambam Health Care Campus \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Rambam Health Care Campus \/ Undisclosed"},{"orgOrder":0,"company":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","sponsor":"Moscow Healthcare Department","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Gam-COVID-Vac M","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Moscow Healthcare Department","highestDevelopmentStatusID":"9","companyTruncated":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation \/ Moscow Healthcare Department"},{"orgOrder":0,"company":"Wacker Chemie AG","sponsor":"MinervaX ApS","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"GBS-NN\/NN2","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Wacker Chemie AG","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wacker Chemie AG \/ MinervaX ApS","highestDevelopmentStatusID":"9","companyTruncated":"Wacker Chemie AG \/ MinervaX ApS"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GS-1720","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GS-1720","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Akeylink Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GST-HG171","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Fujian Akeylink Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujian Akeylink Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Fujian Akeylink Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Akeylink Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GST-HG171","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Fujian Akeylink Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujian Akeylink Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Fujian Akeylink Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Fujian Akeylink Biotechnology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"GST-HG171","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Fujian Akeylink Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fujian Akeylink Biotechnology \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Fujian Akeylink Biotechnology \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HEC74647PA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"HEC74647PA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Sunshine Lake Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"HEC74647PA","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Sunshine Lake Pharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sunshine Lake Pharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sunshine Lake Pharma \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"Frazier Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Financing","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.14000000000000001,"dosageForm":"Injection","sponsorNew":"HilleVax \/ Frazier Healthcare","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Frazier Healthcare"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"HilleVax \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ J.P. Morgan"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Public Offering","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0.12,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.12,"dosageForm":"Injection","sponsorNew":"HilleVax \/ J.P. Morgan","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ J.P. Morgan"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HilleVax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ Undisclosed"},{"orgOrder":0,"company":"HilleVax","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Acquisition","leadProduct":"HIL-214","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"HilleVax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"HilleVax \/ XOMA","highestDevelopmentStatusID":"9","companyTruncated":"HilleVax \/ XOMA"},{"orgOrder":0,"company":"Western Institute for Veterans Research","sponsor":"University of Utah | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Human Papillomavirus 9-valent Vaccine, Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Western Institute for Veterans Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Western Institute for Veterans Research \/ University of Utah | Merck & Co","highestDevelopmentStatusID":"9","companyTruncated":"Western Institute for Veterans Research \/ University of Utah | Merck & Co"},{"orgOrder":0,"company":"Valneva","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"IC43","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Valneva","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Valneva \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Valneva \/ Undisclosed"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"IIBR-100","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"Inactivated Poliomyelitis Vaccine (Sabin Strain)","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Inactivated Salk Polio Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Serum Institute of India \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Serum Institute of India \/ Undisclosed"},{"orgOrder":0,"company":"INMUNOVA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ARGENTINA","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"INM005","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"INMUNOVA","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"INMUNOVA \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"INMUNOVA \/ Undisclosed"},{"orgOrder":0,"company":"Institute of Vaccines and Medical Biologicals, Vietnam","sponsor":"National Institute of Hygiene and Epidemiology, Vietnam | World Health Organization | Department of Health and Human Services | PATH | FHI 360","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Vaccine","year":"2015","type":"Inapplicable","leadProduct":"IVACFLU-A\/H5N1 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Institute of Vaccines and Medical Biologicals, Vietnam","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Vaccines and Medical Biologicals, Vietnam \/ National Institute of Hygiene and Epidemiology, Vietnam | World Health Organization | Department of Health and Human Services | PATH | FHI 360","highestDevelopmentStatusID":"9","companyTruncated":"Institute of Vaccines and Medical Biologicals, Vietnam \/ National Institute of Hygiene and Epidemiology, Vietnam | World Health Organization | Department of Health and Human Services | PATH | FHI 360"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"JN.1 Subvariant SARS CoV-2 rS Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"Swedish Herbal Institute AB","sponsor":"Tbilisi State Medical University | Phytomed AB","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Kan Jang","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Swedish Herbal Institute AB","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Swedish Herbal Institute AB \/ Tbilisi State Medical University | Phytomed AB","highestDevelopmentStatusID":"9","companyTruncated":"Swedish Herbal Institute AB \/ Tbilisi State Medical University | Phytomed AB"},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Probiotic","year":"2020","type":"Inapplicable","leadProduct":"Lacidofil","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ Undisclosed"},{"orgOrder":0,"company":"Puleva Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Lactobacillus Fermentum","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Puleva Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Puleva Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Puleva Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Ume\u00e5 University","sponsor":"BioGaia Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Lactobacillus reuteri DSM17938","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Ume\u00e5 University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ume\u00e5 University \/ BioGaia Pharma","highestDevelopmentStatusID":"9","companyTruncated":"Ume\u00e5 University \/ BioGaia Pharma"},{"orgOrder":0,"company":"Avva Rus JSC","sponsor":"Kirov State Medical Academy | Kirov Regional Clinical Center of Perinatology","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Probiotic","year":"2010","type":"Inapplicable","leadProduct":"Lactofiltrum","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Avva Rus JSC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Avva Rus JSC \/ Kirov State Medical Academy | Kirov Regional Clinical Center of Perinatology","highestDevelopmentStatusID":"9","companyTruncated":"Avva Rus JSC \/ Kirov State Medical Academy | Kirov Regional Clinical Center of Perinatology"},{"orgOrder":0,"company":"LG Chem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"LBVD Hexavalent Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"LG Chem \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"LG Chem \/ Undisclosed"},{"orgOrder":0,"company":"Avva Rus JSC","sponsor":"St. Vladimir Moscow Children's Clinical Hospital | Arhangelsk Regional Children's Clinical Hospital named after Vizshletsov P.G.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Lignin Hydrolytic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Avva Rus JSC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Avva Rus JSC \/ St. Vladimir Moscow Children's Clinical Hospital | Arhangelsk Regional Children's Clinical Hospital named after Vizshletsov P.G.","highestDevelopmentStatusID":"9","companyTruncated":"Avva Rus JSC \/ St. Vladimir Moscow Children's Clinical Hospital | Arhangelsk Regional Children's Clinical Hospital named after Vizshletsov P.G."},{"orgOrder":0,"company":"Yantai Patronus Biotech Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LYB001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Yantai Patronus Biotech Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yantai Patronus Biotech Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Yantai Patronus Biotech Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Yantai Patronus Biotech Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"LYB001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Yantai Patronus Biotech Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yantai Patronus Biotech Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Yantai Patronus Biotech Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Yantai Patronus Biotech Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LYB001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Yantai Patronus Biotech Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yantai Patronus Biotech Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Yantai Patronus Biotech Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Toscana Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MAD0004J08","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Toscana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Toscana Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Toscana Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Toscana Life Sciences","sponsor":"Cross Research S.A.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"MAD0004J08","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Toscana Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Toscana Life Sciences \/ Cross Research S.A.","highestDevelopmentStatusID":"9","companyTruncated":"Toscana Life Sciences \/ Cross Research S.A."},{"orgOrder":0,"company":"Bio Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2019","type":"Inapplicable","leadProduct":"Measles And Rubella Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio Farma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ Undisclosed"},{"orgOrder":0,"company":"Bosnalijek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BOSNIA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Metenkephalin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bosnalijek","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bosnalijek \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Bosnalijek \/ Undisclosed"},{"orgOrder":0,"company":"Moderna Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"mRNA-1273.529","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Moderna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Moderna Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Moderna Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Athersys","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Public Offering","leadProduct":"MultiStem","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Athersys","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Athersys \/ BofA Securities","highestDevelopmentStatusID":"9","companyTruncated":"Athersys \/ BofA Securities"},{"orgOrder":0,"company":"Biomed Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"NA-831","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Biomed Industries","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomed Industries \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Biomed Industries \/ Undisclosed"},{"orgOrder":0,"company":"Shaperon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Nusepin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Shaperon","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shaperon \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Shaperon \/ Undisclosed"},{"orgOrder":0,"company":"Shaperon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Nusepin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Shaperon","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Shaperon \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Shaperon \/ Undisclosed"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Canadian Immunization Research Network | Alberta Children's Hospital | Universit\u00e9 de Montr\u00e9al | IWK Health Centre | University of Calgary | Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"PCV13","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ Canadian Immunization Research Network | Alberta Children's Hospital | Universit\u00e9 de Montr\u00e9al | IWK Health Centre | University of Calgary | Canadian Institutes of Health Research","highestDevelopmentStatusID":"9","companyTruncated":"University of British Columbia \/ Canadian Immunization Research Network | Alberta Children's Hospital | Universit\u00e9 de Montr\u00e9al | IWK Health Centre | University of Calgary | Canadian Institutes of Health Research"},{"orgOrder":0,"company":"Hipra Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"PHH-1V81","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Hipra Scientific","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hipra Scientific \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Hipra Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Inova Health Care Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Plasma","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Inova Health Care Services","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Inova Health Care Services \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Inova Health Care Services \/ Undisclosed"},{"orgOrder":0,"company":"MELISA Institute Genomics & Proteomics Research","sponsor":"Universidad Austral","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Previfenon","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"MELISA Institute Genomics & Proteomics Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"MELISA Institute Genomics & Proteomics Research \/ Universidad Austral","highestDevelopmentStatusID":"9","companyTruncated":"MELISA Institute Genomics & Proteomics Research \/ Universidad Austral"},{"orgOrder":0,"company":"ProFem GmbH","sponsor":"PHARMAZEUTISCHE FABRIK MONTAVIT","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Prof-001","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"ProFem GmbH","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Cream","sponsorNew":"ProFem GmbH \/ PHARMAZEUTISCHE FABRIK MONTAVIT","highestDevelopmentStatusID":"9","companyTruncated":"ProFem GmbH \/ PHARMAZEUTISCHE FABRIK MONTAVIT"},{"orgOrder":0,"company":"Atlantia Food Clinical Trials","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Pylopass","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Atlantia Food Clinical Trials","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atlantia Food Clinical Trials \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Atlantia Food Clinical Trials \/ Undisclosed"},{"orgOrder":0,"company":"Kamada","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2014","type":"Inapplicable","leadProduct":"Rabies Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kamada \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kamada \/ Undisclosed"},{"orgOrder":0,"company":"Optimal Health Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Realife Plus","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Optimal Health Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Optimal Health Research \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Optimal Health Research \/ Undisclosed"},{"orgOrder":0,"company":"Optimal Health Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Realife Plus","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Optimal Health Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Optimal Health Research \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Optimal Health Research \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Province Centers for Disease Control and Prevention","sponsor":"Shenzhen Kangtai Biological Products","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"Recombinant Hepatitis B Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Province Centers for Disease Control and Prevention","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Province Centers for Disease Control and Prevention \/ Shenzhen Kangtai Biological Products","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Province Centers for Disease Control and Prevention \/ Shenzhen Kangtai Biological Products"},{"orgOrder":0,"company":"Supergene, LLC","sponsor":"Russian Academy of Medical Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"Recombinant Non-Immunogenic Staphylokinase","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Supergene, LLC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supergene, LLC \/ Russian Academy of Medical Sciences","highestDevelopmentStatusID":"9","companyTruncated":"Supergene, LLC \/ Russian Academy of Medical Sciences"},{"orgOrder":0,"company":"Serum Institute of India","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Rotavirus Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Serum Institute of India","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Serum Institute of India \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Serum Institute of India \/ Undisclosed"},{"orgOrder":0,"company":"PT. Innovative Pharma Solutions","sponsor":"Archivel Farma | RUTI Immunotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Ruti Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PT. Innovative Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PT. Innovative Pharma Solutions \/ Archivel Farma | RUTI Immunotherapeutics","highestDevelopmentStatusID":"9","companyTruncated":"PT. Innovative Pharma Solutions \/ Archivel Farma | RUTI Immunotherapeutics"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"rVSV-SARS-CoV-2-S Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"NRx Pharmaceuticals \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"9","companyTruncated":"NRx Pharmaceuticals \/ Israel Institute for Biological Research"},{"orgOrder":0,"company":"Centers for Disease Control and Prevention","sponsor":"University of Sierra Leone | Ministry of Health and Sanitation, Sierra Leone | Department of Health and Human Services | eHealth Africa","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"rVSV\u0394G-ZEBOV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Centers for Disease Control and Prevention","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centers for Disease Control and Prevention \/ University of Sierra Leone | Ministry of Health and Sanitation, Sierra Leone | Department of Health and Human Services | eHealth Africa","highestDevelopmentStatusID":"9","companyTruncated":"Centers for Disease Control and Prevention \/ University of Sierra Leone | Ministry of Health and Sanitation, Sierra Leone | Department of Health and Human Services | eHealth Africa"},{"orgOrder":0,"company":"Bio Farma","sponsor":"University of Indonesia | General University Hospital of Valencia | Andalas University | Hasanuddin University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Protein Subunit Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Farma \/ University of Indonesia | General University Hospital of Valencia | Andalas University | Hasanuddin University","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ University of Indonesia | General University Hospital of Valencia | Andalas University | Hasanuddin University"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Universitas Padjadjaran | Udayana University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Protein Subunit Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Farma \/ Universitas Padjadjaran | Udayana University","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ Universitas Padjadjaran | Udayana University"},{"orgOrder":0,"company":"Bio Farma","sponsor":"Universitas Padjadjaran","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"SARS-CoV-2 Protein Subunit Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Farma \/ Universitas Padjadjaran","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ Universitas Padjadjaran"},{"orgOrder":0,"company":"Bio Farma","sponsor":"University of Indonesia | NIHRD, Ministry of Health, Indonesia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"SARS-CoV-2 Protein Subunit Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Farma \/ University of Indonesia | NIHRD, Ministry of Health, Indonesia","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ University of Indonesia | NIHRD, Ministry of Health, Indonesia"},{"orgOrder":0,"company":"Bio Farma","sponsor":"University of Indonesia | General University Hospital of Valencia","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDONESIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"SARS-CoV-2 Protein Subunit Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bio Farma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bio Farma \/ University of Indonesia | General University Hospital of Valencia","highestDevelopmentStatusID":"9","companyTruncated":"Bio Farma \/ University of Indonesia | General University Hospital of Valencia"},{"orgOrder":0,"company":"Institute of Vaccines and Medical Biologicals, Vietnam","sponsor":"Pasteur Institute, Ho Chi Minh City | PATH | Quintiles Inc | World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Vaccine","year":"2017","type":"Inapplicable","leadProduct":"Seasonal Inactivated, Split Virion, Trivalent Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Institute of Vaccines and Medical Biologicals, Vietnam","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Institute of Vaccines and Medical Biologicals, Vietnam \/ Pasteur Institute, Ho Chi Minh City | PATH | Quintiles Inc | World Health Organization","highestDevelopmentStatusID":"9","companyTruncated":"Institute of Vaccines and Medical Biologicals, Vietnam \/ Pasteur Institute, Ho Chi Minh City | PATH | Quintiles Inc | World Health Organization"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Vaccine","year":"2010","type":"Inapplicable","leadProduct":"Serogroup B Meningococcal Recombinant Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Helixmith","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Tadios","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Helixmith","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Helixmith \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Helixmith \/ Undisclosed"},{"orgOrder":0,"company":"University of Crete","sponsor":"Galenica SA | Olvos Science SA","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"GREECE","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Thymbra 59 capitata (L.) Cav","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Crete","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Crete \/ Galenica SA | Olvos Science SA","highestDevelopmentStatusID":"9","companyTruncated":"University of Crete \/ Galenica SA | Olvos Science SA"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"tNIV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"PHARMENTERPRISES LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Treamid","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PHARMENTERPRISES LLC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PHARMENTERPRISES LLC \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"PHARMENTERPRISES LLC \/ Undisclosed"},{"orgOrder":0,"company":"PHARMENTERPRISES LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Treamid","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PHARMENTERPRISES LLC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PHARMENTERPRISES LLC \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"PHARMENTERPRISES LLC \/ Undisclosed"},{"orgOrder":0,"company":"Mahidol University","sponsor":"The Government Pharmaceutical Organization | World Health Organization","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"THAILAND","productType":"Vaccine","year":"2018","type":"Inapplicable","leadProduct":"Tri Fluvac Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Mahidol University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mahidol University \/ The Government Pharmaceutical Organization | World Health Organization","highestDevelopmentStatusID":"9","companyTruncated":"Mahidol University \/ The Government Pharmaceutical Organization | World Health Organization"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"V591","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"V591","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"V591","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"V591","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"EuBiologics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Vi-CRM Typhoid Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"EuBiologics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EuBiologics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"EuBiologics \/ Undisclosed"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Whole Virion, Inactivated SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Bharat Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Bharat Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Whole Virion, Inactivated SARS-CoV-2 Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bharat Biotech","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bharat Biotech \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Bharat Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Novavax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"XBB.1.5 Booster Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Novavax","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novavax \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Novavax \/ Undisclosed"},{"orgOrder":0,"company":"PHARMENTERPRISES LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"RUSSIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"XC8","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"PHARMENTERPRISES LLC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PHARMENTERPRISES LLC \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"PHARMENTERPRISES LLC \/ Undisclosed"},{"orgOrder":0,"company":"Qilu Hospital of Shandong University","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"Vascular endothelial growth factor A","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Qilu Hospital of Shandong University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Qilu Hospital of Shandong University \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Qilu Hospital of Shandong University \/ Undisclosed"},{"orgOrder":0,"company":"Nitric Oxide Innovations","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"TURKEY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sodium Nitrite","moa":"Vasodilator","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Nitric Oxide Innovations","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nitric Oxide Innovations \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Nitric Oxide Innovations \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Novotech","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Novotech"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ifenprodil Tartrate","moa":"vasodilators (undefined group)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Algernon Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Algernon Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Algernon Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Wits Health Consortium","sponsor":"PharmaCentrix | Perinatal HIV Research Unit, Witswatersrand","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Triazavirin","moa":"Viral RNA synthesis","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Wits Health Consortium","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Wits Health Consortium \/ PharmaCentrix | Perinatal HIV Research Unit, Witswatersrand","highestDevelopmentStatusID":"9","companyTruncated":"Wits Health Consortium \/ PharmaCentrix | Perinatal HIV Research Unit, Witswatersrand"},{"orgOrder":0,"company":"Barts & The London NHS Trust","sponsor":"National Health Service, UK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Barts & The London NHS Trust","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oil","sponsorNew":"Barts & The London NHS Trust \/ National Health Service, UK","highestDevelopmentStatusID":"9","companyTruncated":"Barts & The London NHS Trust \/ National Health Service, UK"},{"orgOrder":0,"company":"Regionshospital Nordjylland","sponsor":"Charite University, Berlin, Germany | Leiden University Medical Center | Nagasaki University | Ume\u00e5 University | Merck Group | Ministry of Health, Madagascar","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Praziquantel","moa":"Voltage-activated calcium channel beta 1 subunit | Voltage-activated calcium channel beta 2 subunit","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Regionshospital Nordjylland","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Regionshospital Nordjylland \/ Charite University, Berlin, Germany | Leiden University Medical Center | Nagasaki University | Ume\u00e5 University | Merck Group | Ministry of Health, Madagascar","highestDevelopmentStatusID":"9","companyTruncated":"Regionshospital Nordjylland \/ Charite University, Berlin, Germany | Leiden University Medical Center | Nagasaki University | Ume\u00e5 University | Merck Group | Ministry of Health, Madagascar"},{"orgOrder":0,"company":"University of Catanzaro","sponsor":"Azienda Ospedaliera Universitaria Mater Domini, Catanzaro | Azienda Sanitaria Provinciale Di Catanzaro | Annunziata Hospital, Cosenza, Italy | Azienda Ospedaliera Bianchi-Melacrino-Morelli","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"University of Catanzaro","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Catanzaro \/ Azienda Ospedaliera Universitaria Mater Domini, Catanzaro | Azienda Sanitaria Provinciale Di Catanzaro | Annunziata Hospital, Cosenza, Italy | Azienda Ospedaliera Bianchi-Melacrino-Morelli","highestDevelopmentStatusID":"9","companyTruncated":"University of Catanzaro \/ Azienda Ospedaliera Universitaria Mater Domini, Catanzaro | Azienda Sanitaria Provinciale Di Catanzaro | Annunziata Hospital, Cosenza, Italy | Azienda Ospedaliera Bianchi-Melacrino-Morelli"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Memo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Memo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Management Sciences for Health","sponsor":"KNCV Tuberculosis Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Management Sciences for Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Management Sciences for Health \/ KNCV Tuberculosis Foundation","highestDevelopmentStatusID":"9","companyTruncated":"Management Sciences for Health \/ KNCV Tuberculosis Foundation"},{"orgOrder":0,"company":"Hershey Medical Center","sponsor":"AXIOM Real Time Metrics | Analytica Ventures","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Hershey Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hershey Medical Center \/ AXIOM Real Time Metrics | Analytica Ventures","highestDevelopmentStatusID":"9","companyTruncated":"Hershey Medical Center \/ AXIOM Real Time Metrics | Analytica Ventures"},{"orgOrder":0,"company":"LifeFactors","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"COLOMBIA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"LifeFactors","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LifeFactors \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"LifeFactors \/ Undisclosed"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Recombinant Human Interferon Alpha-2b","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Recombinant Human Interferon Alpha-2b","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Gel","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Lee's Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Recombinant Interferon alfa-2b","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Lee\\'s Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lee\\'s Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Lee\\'s Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Hepenofovir fumarate","moa":"HBV DNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Xi'an Xintong Pharmaceutical Research Co.,Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Xi'an Xintong Pharmaceutical Research Co.,Ltd. \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Xi'an Xintong Pharmaceutical Research Co.,Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"EYEGENE","sponsor":"BMI Korea","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"EYEGENE","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"EYEGENE \/ BMI Korea","highestDevelopmentStatusID":"9","companyTruncated":"EYEGENE \/ BMI Korea"},{"orgOrder":0,"company":"BioNet-Asia","sponsor":"National Science and Technology Development Agency, Thailand | Mahidol University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"THAILAND","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"BK1301","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"BioNet-Asia","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioNet-Asia \/ National Science and Technology Development Agency, Thailand | Mahidol University","highestDevelopmentStatusID":"9","companyTruncated":"BioNet-Asia \/ National Science and Technology Development Agency, Thailand | Mahidol University"},{"orgOrder":0,"company":"Peptilogics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"PLG0206","moa":"Bacterial cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Peptilogics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Peptilogics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Peptilogics \/ Undisclosed"},{"orgOrder":0,"company":"Alfasigma","sponsor":"Clinedem","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sulodexide","moa":"Antithrombin-III (ATIII)","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Alfasigma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alfasigma \/ Clinedem","highestDevelopmentStatusID":"9","companyTruncated":"Alfasigma \/ Clinedem"},{"orgOrder":0,"company":"The Emmes Company, LLC","sponsor":"Michael Cohen-Wolkowiez","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Ampicillin","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"The Emmes Company, LLC","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Emmes Company, LLC \/ Michael Cohen-Wolkowiez","highestDevelopmentStatusID":"9","companyTruncated":"The Emmes Company, LLC \/ Michael Cohen-Wolkowiez"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Silvia M. Pinango L.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2010","type":"Inapplicable","leadProduct":"Ertapenem","moa":"Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Merck & Co \/ Silvia M. Pinango L.","highestDevelopmentStatusID":"9","companyTruncated":"Merck & Co \/ Silvia M. Pinango L."},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Philip Grant","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Rilpivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Philip Grant","highestDevelopmentStatusID":"9","companyTruncated":"Gilead Sciences \/ Philip Grant"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Skyepharma

                            France
                            CPhI WW Frankfurt
                            Booth #6.1D44
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSkyepharma, an Expert and Innovative CDMO Partner for tailor-made solutions in complex oral solids and bioproduction.

                            Lead Product(s) : 20-Hydroxyecdysone

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Biophytis

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Biophytis and Skyepharma Sign a Partnership Agreement for The Production of Sarconeos (BIO101)

                            Details : Under the partnership, Skyepharma will develop finished product batches meeting the GMP standards of Sarconeos (20-hydroxyecdysone), an orally administered small molecule, for severe forms of Covid-19.

                            Product Name : Sarconeos

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 25, 2023

                            Lead Product(s) : 20-Hydroxyecdysone

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Biophytis

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            Skyepharma Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Seqens

                            France
                            CPhI WW Frankfurt
                            Booth #11.0C76
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSeqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

                            Lead Product(s) : 20-Hydroxyecdysone

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Biophytis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Biophytis and SEQENS Sign a Partnership to Produce Sarconeos (BIO101) Active Compound

                            Details : The agreement aims for the production of the active compound in Sarconeos (20-hydroxyecdysone), Biophytis' main drug candidate developed for three indications, severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy.

                            Product Name : Sarconeos

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            July 18, 2023

                            Lead Product(s) : 20-Hydroxyecdysone

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Biophytis

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Seqens Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Acoziborole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : DNDi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Acoziborole: Investigational Single-dose Oral Treatment Raises Hope For Elimination Of Sleeping Sickness In Af...

                            Details : Acoziborole, a potentially transformative investigational treatment for sleeping sickness, has a favourable safety profile, with no significant drug-related safety signals reported.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 30, 2022

                            Lead Product(s) : Acoziborole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : DNDi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : SARS-CoV-2 Recombinant Protein Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19...

                            Details : SARS-CoV-2 Recombinant Protein Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            February 21, 2021

                            Lead Product(s) : SARS-CoV-2 Recombinant Protein Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : GSK

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            FARMAK, a.s

                            Czech Republic
                            CPhI WW Frankfurt
                            Booth #12.1F9
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothFarmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

                            Lead Product(s) : Enisamium Iodide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Enisamium Iodide for the Treatment of Acute Respiratory Viral Infections, Including Inf...

                            Details : Enisamium Iodide is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Respiratory Tract Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 23, 2020

                            Lead Product(s) : Enisamium Iodide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Farmak Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Dr. Reddy's Laboratories

                            India
                            CPhI WW Frankfurt
                            Booth #9.1B48
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Russian Direct Investment Fund

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr. Reddy's and RDIF Commence Clinical Trials for Sputnik V Vaccine in India

                            Details : After obtaining the requisite clearance from the Central Drugs Laboratory, Dr. Reddy's Laboratories and RDIF have begun adaptive phase 2/3 clinical trials for the Sputnik V vaccine in India. The trial is a multicenter and randomised controlled safety and...

                            Product Name : Sputnik V

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 01, 2020

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Russian Direct Investment Fund

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Dr. Reddy's Laboratories

                            India
                            CPhI WW Frankfurt
                            Booth #9.1B48
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Russian Direct Investment Fund | JSS Medical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute R...

                            Details : Gam-COVID-Vac is a Vaccine drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 23, 2020

                            Lead Product(s) : Gam-COVID-Vac

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Russian Direct Investment Fund | JSS Medical Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sanofi

                            France
                            CPhI WW Frankfurt
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Sarilumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sanofi, Regeneron Begin Global Kevzara Clinical Trial Program In Patients With Severe Covid-19

                            Details : The US based trial will begin at medical centers in New York and will assess the safety and efficacy of adding Kevzara to usual supportive care, compared to supportive care plus placebo.

                            Product Name : Kevzara

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 16, 2020

                            Lead Product(s) : Sarilumab

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glecaprevir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjec...

                            Details : Glecaprevir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hepatitis C.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 01, 2017

                            Lead Product(s) : Glecaprevir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AbbVie Inc

                            U.S.A
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ombitasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects

                            Details : Ombitasvir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hepatitis C, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 01, 2015

                            Lead Product(s) : Ombitasvir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth